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MASS SPECTROMETRIC ANALYSIS OF ANTICANCER AGENTS AND 
DRUGS OF ABUSE IN BIOMATRICES, AS WELL AS 
CHARACTERIZATION OF INACTIVATION OF B-LACTAMASE ENZYMES 
 
KERRI M. SMITH 
 
ABSTRACT 
 
Mass spectrometry is a valuable tool in the analysis of many types of 
compounds. From small molecules to large proteins, mass spectrometry 
can help to interrogate samples and give insights to the origins of disease 
as well as calculate an exact concentration. Bioanalytical method 
development is an integral component in the measurement of such 
compounds. To facilitate proper analytical investigation, the process of 
method development, analysis, and interpretation must be understood. 
This work describes the basis and procedure for bioanalytical method 
development and its detailed application to preclinical studies of the 
antineoplastic agent hexamethylene bisacetamide and measurement of 
illicit drugs of abuse benzylpiperazine and trifluoromethylphenyl 
piperazine using liquid chromatography tandem mass spectrometry. 
Additionally, procedures for analyzing protein-drug interactions and their 
implication in antibiotic resistance are discussed.
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CHAPTER I 
 
INTRODUCTION OF LIQUID CHROMATOGRAPHY MASS 
SPECTROMETRY FOR BIOANALYTICAL ANALYSIS 
 
1.1   General introduction 
 
The insight of how drugs distribute, transform, and are removed from the 
biological system is integral in our understanding of how to effectively 
treat diseases. Analytical interrogation can give information of the toxicity, 
minimum effective dose, and pharmacokinetics (metabolism and 
elimination properties) of drugs and chemicals, while furthering drug 
discovery and development. The challenges regarding analysis include 
the removal of the drug from the biological matrix, its separation from the 
matrix components, and finally detection and quantification. Success in 
each step of the analysis is dependent on parameters including nature of 
biological Analytical determination of drugs in biological samples may be 
accomplished using a variety of techniques and instrumentation: Gas 
  2 
Chromatography [1], Liquid Chromatography [2, 3], and Capillary 
Electrophoresis [3]. When these separation techniques are coupled to a 
detector such as mass spectrometry, their power of investigation 
increases. 
 
1.2.   Modern methods for sample analysis 
 
A popular and versatile tool that facilitates analytical measurement is 
liquid chromatography separation coupled to mass spectrometry detection 
[4]. This technique has the advantage that it may be partially or fully 
automated for cost-effective high-throughput and minimal analyst 
intervention once the methodology is developed [5].   
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1.2.1.   High Performance Liquid Chromatographic separation 
 
High Performance Liquid Chromatography (HPLC) separates compounds 
based on their differential interactions with a stationary phase (the 
column). Here, the compound of interest (the analyte) is separated from 
the other components of the matrix (e.g., blood, serum, urine, etc) (figure 
1.1). HPLC systems typically consist of reservoirs for mobile phase, a 
pumping system, an autosampler for sample introduction to the analytical 
column for separation, a diverter or switching valve, and finally a detector. 
Some detectors are listed in table 1.1, but this work will focus on mass 
spectrometric detection and is described in detail in section 1.2.2. 
 
On injection of the sample, the analyte interacts with the stationary phase 
and produces a detector response proportional to concentration on elution. 
The molecules separate and elute in the form of a Gaussian distribution in 
an ideal situation (figure 1.2). Typically, additional or competing 
interactions influence the final shape of the peak. These interactions and 
tactics for their improvement are described. 
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Figure 1.1, Graphic of a typical HPLC instrument setup. 
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Figure 1.2, Illustration of retentivity and diffusion on HPLC separation 
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Table 1.1, Common detectors for HPLC 
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1.2.1.1. HPLC modes and separation  
 
There are many forms of HPLC separation including size exclusion (SEC), 
ion exchange (IEX), affinity, normal-phase (NPLC), and the most common 
form, reversed-phase HPLC (RPLC) [6].  RPLC is characterized by a polar 
(hydrophilic) mobile phase and a non-polar (hydrophobic) stationary 
phase, and its description will be the focus of this work. In RPLC, the 
compound of interest is separated by interaction with the ligand on the 
stationary phase in different ways. Figure 1.3 shows some general 
common available stationary phase ligands. Seven of the common 
interactions that are believed to produce retention and selectivity are 
depicted in figure 1.4 and described below [2]: 
 
 i]  Dipole – Dipole interaction – Dipole of analyte interacting with 
the dipole of the cyano ligand. 
 ii] Cation Exchange – Silanol groups can be negatively charged   
(-SiO-) and will interact with a basic analyte [7]. Additionally, 
charged silanol groups can repulse an ionized acidic analyte 
(e.g., R-COO-). Both interactions influence peak shape mainly 
by causing excessive tailing. 
 iii] Hydrophobic interactions  
 iv] Steric exclusion – A bulky analyte can not interact with the 
stationary phase due to chemical structure/shape. This can 
  8 
influence the separation and selectivity of isomers (e.g., 
polyaromatic hydrocarbons with same number of phenyl rings, 
but different structure). 
 v]   π – π interaction – Aromatic rings or other structures having π 
electrons may interact with a C6-Phenyl column much differently 
than a C18. 
 
1.2.1.2. Challenges in HPLC separation 
 
A large number of important pharmaceutical and abusable drugs are basic 
and carry a positive charge at physiological pH [8], including the 
compounds described in this work.  Basic compounds present two specific 
challenges in efficient chromatographic separation: cation exchange with 
residual silanols on the column substrate that result in tailing [8] and 
degradation of the silica substrate under alkaline mobile phase conditions 
[9]. Technological advances to address these situations lead to end 
capping the unreacted silanols with a small group to block their ion 
exchange activity and the development of new hybrid substrates that 
withstand high pH [10]. Other tactics such as solvent type, pH, and mobile 
phase modifiers are discussed. 
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Figure 1.3, Common (simplified) RPLC ligand types 
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Figure 1.4, RPLC analyte – stationary phase interactions 
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1.2.1.2.1 Choice of solvent, modifier, and pH 
 
Solvent type can influence the selectivity in RPLC. The two most common 
solvents used in HPLC are methanol (MeOH) and acetonitrile (ACN). 
MeOH is polar protic where ACN is polar aprotic. The elution strength of 
MeOH is weaker than that of ACN, as well, it’s absorbance continues to 
220 nm in the UV spectrum, where ACN is much lower [11]. Figure 1.5 
depicts a nomogram of the relative elution strength of MeOH and ACN 
referenced against tetrahydrofuran (THF) [12]. Importantly, due to the 
ability of MeOH to donate and accept hydrogen bonds, selectivity in HPLC 
separation can change with the two solvents. Figure 1.6 shows an 
example of change in elution order for the separation of phenol, benzoic 
acid, and p-toluic acid when ACN is used instead of Methanol 
(http://www.shimadzu.com/an/hplc/support/lib/lctalk/35/35lab.html). 
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Figure 1.5, Nomogram of the elution strength of acetonitrile and methanol 
in water compared to tetrahydrofuran. 
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Figure 1.6, Change in elution order when using methanol versus 
acetonitrile 
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Mentioned previously, cation exchange is a known interaction and can be 
problematic in the analysis of basic compounds. Changing the pH below 
the pKa of –SiO- to yield –SiOH and reduce the interaction complicates 
the situation by creating a highly charged analyte that will elute sooner 
due to reduced interactions with the stationary phase ligand. The addition 
of mobile phase modifiers to compete with the exchange of the residual 
silanols can help to improve peak shape [7]. A list of modifiers is in table 
1.2.  
 
Finally, changing the pH of the mobile phase can change the retentivity of 
analytes on the stationary phase. Large changes in selectivity can be 
acquired by simply changing the pH [13]. To retain compounds longer, 
one may choose a pH above the pKa for basic analytes and below the pKa 
for acidic. This will create an uncharged analyte that will have an 
opportunity to interact with the stationary phase longer. Table 1.3 lists 
common buffers and their properties. 
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Table 1.2, List of common mobile phase modifiers 
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Table 1.3, List of common buffers 
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1.2.2.  Mass spectrometric detection 
 
Mass spectrometry can be thought of as a molecular balance. The 
technique can determine the mass of a compound, and even give 
information and clues to its molecular makeup by encouraging the 
fragmentation of compounds in a prescribed manner [14].  
 
Mass spectrometers are made of four basic components and summarized 
in figure 1.7. The instrument uses an electromagnetic field to discriminate 
between ions with different mass to charge ratios (m/z). The sample is 
introduced in liquid form by direct infusion or by HPLC effluent. The 
solution is evaporated and ions formed in the ion source. Once inside the 
vacuum, the electromagnetic field of the mass analyzer is tuned to 
separate the ions based on their m/z, and are sent to the detector for 
counting and recording by the computer. The abundance of smaller 
molecules in bioanalysis means that an additional step is needed to 
increase the specificity. Here, an ion is selected using the electromagnetic 
field and fragmented. The fragments can then be scanned in a second 
mass analyzer for a second degree of confidence in analysis [14].   
 
A consideration when using HPLC coupled to mass spectrometry is the 
choice of solvent and mobile phase modifier or buffer. Since it is 
  18 
necessary to evaporate and create ions for mass spectrometric analysis, 
all components must be volatile organic salts and compounds. 
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Figure 1.7, Block diagram of a mass spectrometer setup 
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1.2.2.1. Ionization methods 
 
There are many ionization methods available today [15], but this work will 
focus on the two most commonly used: electrospray ionization (ESI) and 
atmospheric pressure chemical ionization (APCI).  
 
ESI  
 
ESI is considered a “soft ionization” technique where the solution passes 
through a charged capillary and is nebulized producing charged droplets 
(figure 1.8).  On exiting the capillary, the solution forms a Taylor cone [16]. 
The apex of the Taylor cone is highly charged and pushes a jet of charged 
droplets that expand to a plume (figure 1.9). As the result of heated drying 
or desolvation gas, the solvent in the droplets of the plume dries leaving 
the charged species. The ions then enter the mass analyzer under the 
influence of vacuum and voltage difference. Once inside, the diffuse ion 
cloud is focused and then filtered by the quadrupoles.  
 
ESI is useful for producing ions of labile molecules, small polar and some 
non-polar compounds, all the way to large biomolecules. The technique 
can produce cation adducts (e.g., H, Na, Li, NH3, K) (figure 1.10) [17] , 
solvent adducts (e.g., acetonitrile, methanol, H2O), and combinations of 
any/all [18-21]. Sodium (Na) adducts can be especially troublesome as 
  21 
they tend to create a very strong and stabilizing association with the 
molecule and can prevent fragmentation. Even so, this and similar 
adducts can be encouraged to increase the sensitivity of some 
compounds [22]. A tactic to encourage molecular ions (M+H) for a less 
complicated spectrum and for compounds where the adduct formation is 
too stabilizing is to use a buffer containing NH3: ammonium acetate or 
ammonium formate. This will encourage the formation of the molecular ion, 
M + H. 
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Figure 1.8, Electrospray ionization configuration. 
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Figure 1.9, Formation of ions in ESI. Adapted from reference: [23]. 
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Figure 1.10, Example of sodium (Na) adduct formation in ESI of the 
compound hexamethylene bisacetamide. Data acquired by the author. 
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Figure 1.11, Positive ESI mass spectrums of (A) a small molecule and (B) 
a protein. Data acquired by the author. 
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ESI is able to add or abstract a charge from all the available sites on a 
compound. This can create multiply charged species, a feature that is very 
useful for biomolecule mass spectrometric analysis as most quadrupole 
mass spectrometers are limited in the m/z range they can measure. Figure 
1.11 shows mass spectrum examples of a small molecule of 756 m/z and 
a large protein with multiple H adducts. Viewing the mass spectrum of the 
protein as in figure 1.10 B can make it difficult for comparison and 
analysis. Since there are multiple sites on a protein for protonation, many 
of those sites do protonate creating a mass spectrum of multiply charged 
species. Calculating the charge states and the full protein mass is as 
follows (http://www.astbury.leeds.ac.uk/facil/MStut/mstutorial.htm): 
 
 
 
  
  
 
         
 (1) 
 
If the charge state is unknown, we may solve simultaneous equations to 
eliminate the MW term. Using the example in figure 1.12 and assuming 
m / z =  mass to charge ratio of protein peak in spectrum
a =  adduct (use 1.0079 for H)
MW =  molecular weight of protein
n =  number of charges 
m / z = (MW + na)n
  27 
adjacent peaks are part of the same charge series and are separated by 
one charge, we calculate the charges by: 
 
         (2) 
 
       (3) 
 
 
 
        (4) 
 
 
 
        (5) 
 
 
 
         (6) 
 
Ym/z =
(MW + na)
n
Xm/z =
(MW + na)
n
nYm/z − na = (n +1)Xm/z − (n +1)a
solving for nYm/z :
nYm/z = nXm/z + Xm/z − a
therefore:
n(Ym/z + Xm/z ) = Xm/z − a
solving for n gives us the charge of Ym/z :
n = Xm/z − aXm/x −Ym/z
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Using the value for n as determined in equation 6, we can use equation 1 
to determine the molecular weight of the protein. 
 
 
 
 
 
 
Figure 1.12, Illustration of charge distribution peaks of a protein. 
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Utilizing the two highest peaks in figure 1.10 B, the calculation is as 
follows: 
 
          
     
We calculate number of charges (n) of peak Y using equation 6: 
      
  
  
Using the number of charges and the m/z of Y, we can calculate the 
molecular weight of the protein: 
 
      
 
Many mass spectrometric software programs have automatic calculation, 
called charge deconvolution. Using the Bioanalyst QS v.2.0 (AB Sciex, 
Foster City, CA), the results of the charge deconvolution, illustrated in 
figure 1.13, is 28,872.10 Da, an error of 0.4 Da or 0.001%. 
 
 
Xm/z = 1070.33
Ym/z = 1032.14
n = 1070.33−1.00791070.33−1032.14 = 28
(1032.12 *28)− (28 *1.0079) = 28871.70 Da
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Figure 1.13, Automated mass calculation  
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APCI 
 
APCI is similar to ESI, but with one prominent difference: ions are created 
after nebulization of the solution (figure 1.14). A corona current starts at 
the discharge needle tip, abstracts an electron and ionizes N2 and O2 
each to N2 + and O2 +. These primary ions collide with the vaporized 
solvent and form intermediate ions, which then collide with the sample 
molecules forming sample ions [24]. Figure 1.15 shows an example of 25-
hydroxyvitmin D2 using both ESI and APCI ion sources. On ionization in 
APCI, the 25-hydroxyvitamin D2 loses one molecule of water (-18). 
 
APCI is useful for non-polar to moderately polar compounds of rather 
lower molecular weight (up to approximately 1500 Da), but it is not 
amenable to compounds that are charged in solution [24]. Additionally, 
higher flow rates may be used, allowing for faster analysis times. A major 
advantage of APCI over ESI is its resilience against matrix effects. In ESI, 
the solution is charged through a metal capillary, then nebulized and dried 
before analysis. This presents competition for charges; a feature that 
APCI can avoid by creating ions in the gaseous phase. 
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Figure 1.14, Atmospheric pressure chemical ionization.  
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Figure 1.15, An example of 25-hydroxyvitamin D2 ionization by ESI and 
APCI. Data acquired by the author. 
 
1.2.2.2. Mass analyzers 
 
Mass analyzers most commonly used are quadrupole (Q), ion trap (IT) 
and linear ion trap (LIT), time-of-flight (TOF), and combinations as Q-TOF 
and Q-LIT. This work will focus on Q, IT/LIT, and TOF analyzers. 
 
Quadrupole 
 
Quadrupole mass analyzers have four poles arranged in a square 
formation. Opposite pairs are connected electrically and have 
radiofrequency (RF) and direct current (DC) potentials applied, with the 
pairs 180 ° out of phase (figure 1.15) forming a quadrupole 
electromagnetic field based on the laws on motion, equations 7 and 8, 
where ϕ = potential applied to the rods, U = DC Voltage and (VcosT) = RF 
Voltage [24]. These oscillating and opposite electric fields create an 
electric potential (F) along the x-y axis (eq. 9) (see figure 1.15).  On 
introduction of the newly formed ions (by ESI or other source), the phase 
difference influences the trajectories of the ions through the quadrupoles. 
The quadrupole voltages are programmed to make stable trajectories for 
ions with certain m/z ratios. Any ion that falls outside of this stable region 
will oscillate too largely and strike the rods (for instance, when the values 
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of either x or y reach r, as in eq. 9 and depicted in figure 1.16). Stable 
ions will move through the rods to the detector for counting and analysis 
[25]. 
 
        (7) 
 
       (8) 
 
     (9) 
 
 
 
 
 
 
  
φ =U − (V cosωT )
φ = −U + (V cosωT )
F = [(x2 − y2 ) / r2 ](U +V cosωT )
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Figure 1.16, Graphic representation of the quadrupole arrangement 
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Ion trap: cubic and linear 
 
Ion trap analyzers works similarly to the quadrupole, but have a 3D 
geometry (figure 1.17). Ions from the source are introduced to the ion trap 
and form stable 3D trajectories. Similar to the quadrupole, ions with 
specific m/z can be selected, but unlike the quadrupole, the ions are 
trapped and expelled to the detector [26].  A disadvantage to using the ion 
trap is the formation of the “ion cloud” inside the trap itself. Ions not only 
respond to the RF oscillations of the ring and endcap electrodes, but they 
repel each other as well. To overcome this, extra inert gas (N2, He2) is 
added to collide with and offer collisional cooling [24]. On cooling, the ions 
remain stable and avoid expanding their trajectories to collide with the 
sides of the trap.  
 
The linear trap is essentially a modified quadrupole with additional lenses 
at the beginning and end tuned to the same polarity as the analysis 
(positive for positive ions, and negative for negative ions). The like 
polarities repel each other thus trapping the ions [24].  
 
The multiplexing of mass analyzers can increase their functionality and 
sensitivity. Aligning two quadrupoles in sequence with a collision cell in 
between allows the first quadrupole (Q1) to filter the molecular ion of 
choice, send it to the collision cell for fragmentation by collision-induced 
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dissociation (CAD), and finally, all fragments or the most abundant (or 
unique) fragment ion may be scanned by the second quadrupole (Q2). A 
common mass spectrometric experimental setup in quantitative analysis 
has Q1 set to the molecular ion of choice, fragmentation by CAD, and Q3 
selection of a fragment ion. This Multiple Reaction Monitoring (MRM, also 
denoted MS/MS) is very sensitive and highly specific. Other common 
setups such as Q-IT and Q-LIT offer similar functionality. But just as the 
ions are able to be trapped, they are able to be fragmented inside the trap. 
These fragments oscillate inside and can be fragmented again before 
ejection and analysis. Figure 1.18 depicts the arrangement of two 
quadrupoles in series with the second quadrupole having the ability to 
also function as a linear ion trap. 
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Figure 1.17, Graphic representation of an ion trap analyzer 
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Figure 1.18, Multiplexing of two quadrupoles in series, where the second 
quadrupole can function as a linear ion trap. 
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Time of Flight 
 
Time of Flight (TOF) analyzers separate and distinguish ions of differing 
m/z based on their flight times through a field-free vacuum [15]. Unlike 
quadrupole mass analyzers where scanning RF and DC voltages guide 
ions of differing m/z through an electromagnetic region to the detector, 
TOF analyzers distinguish each m/z present in discrete packets of ions as 
they arrive at the detector.  
 
It is important for all the ions in each packet to have the same kinetic 
energy as their m/z is calculated by difference in flight time. Equation 10 
is the mathematical definition of kinetic energy of an ion [24, 27]: 
qE = 12 mv
2  , where  qE  = qV  = zeV         (10) 
Where m = mass, v = velocity, q = ze = charge, and E = V = electric 
potential energy. We know that: 
velocity, v = distance traveled,  Ltime, t         (11) 
So rearrangement of equation 10 with incorporation of equation 11 yields, 
zeE = 12m
L
t
⎛
⎝⎜
⎞
⎠⎟
2
         (12) 
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and further: 
m z =
2eEt 2
L2           (13) 
So we can see that the drift time of an ion in a field free vacuum is related 
to the m/z of that ion. To achieve equal initial kinetic energies, ions 
created at the source are guided towards a region where they are directed 
orthogonally into the flight tube [28]. This orthogonal acceleration 
introduces kinetic energy of the same amount to each ion, but importantly, 
this kinetic energy is a different vectoral component and is separate from 
the initial velocity. Highly resolved m/z can be calculated from the 
difference in time of the orthogonal acceleration and detector strike. A 
great benefit to this development is the ability to use continuous flow into 
the ion source, as liquid chromatography – electrospray ionization. Ions 
are created continuously at the source and directed towards the flight tube. 
They can be filtered first by a quadrupole, and then momentarily slowed 
down (or trapped) in packets before entrance into the accelerator. Figure 
1.19 is a schematic of a typical orthogonal-acceleration quadrupole-TOF 
mass spectrometer.  
 
In typical configurations of the flight tube, ions are accelerated down 
towards an electrical “mirror,” also called a reflectron [29]. Here the ions 
drift into an electrical gradient of the same charge and cause repulsion. 
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Although initial kinetic energy of ions with the same m/z can be somewhat 
corrected by the use of the orthogonal acceleration, these are often 
produced at different places in the source. This kinetic energy dispersion 
[24] reduces resolution because of spread. To overcome this, ions are 
accelerated into the field-free region to a reflectron and re-directed back 
towards their original path. Ions with more kinetic energy will penetrate 
further into the reflectron and emerge to strike the detector the same time 
as their lower kinetic energy brother m/z. 
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Figure 1.19, Schematic of typical orthogonal acceleration quadrupole-TOF 
mass spectrometer. 
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Resolving power, or mass resolution, is the ratio of peak mass to the 
width at half mass (equation 14). 
resolution = m
Δm          (14) 
Quadrupole instruments are typically ran at unit resolution meaning that at 
the Full Width at Half Maximum of the peak (FWHM), the Δm = 0.7 Da. 
This corresponds to a resolution of roughly 1000 at lower masses, and 
grows as the mass becomes larger. TOF instruments operate at least 10 
times quadrupole resolution and are considered to be high mass accuracy 
instruments [24]. Figure 1.20 demonstrates the resolving power of a 
quadrupole and TOF mass spectrometer using Benzylpiperazine. 
Benzylpiperazine is discussed in Chapter III. 
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Figure 1.20, Illustration of resolution of a quadrupole vs. quadrupole-TOF 
mass spectrometer using benzylpiperazine (C11H16N2). 
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1.2.3.  Quantitative bioanalytical HPLC-MS/MS method validation 
 
Utilization of HPLC tandem mass spectrometry (MS/MS, or MRM) requires 
that the method used to quantify the analyte be sufficiently reproducible 
and reliable. To ensure reproducibility and reliability, standards of known 
concentrations are added to the biomatrix intended for the study, 
extracted, and analyzed using the instrumental setup to determine their 
concentration – response correlations. A standard curve of calibrators is 
created to determine the concentration range of the analysis, and three 
quality control (QC) samples, also of known concentration, spanning the 
range of the curve are compared. Parameters to be examined include 
recovery of the analyte from the biomatrix, selectivity of the measured 
analyte from the matrix, accuracy and precision of the measurement, 
reproducibility, and stability replicating the study and storage conditions.  
 
The U.S. FDA developed a draft of recommended bioanalytical method 
validation guidelines in 2001 [30] with a more recent update and summary 
[31]. The abbreviated guidelines and considerations are listed in figure 
1.21 (from reference [28]). 
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Figure 1.21, Typical U.S. FDA bioanalytical method validation 
requirements (from reference [28]). 
Parameter or Process Requirement
Selective (matrix interference) Review noninterference in at least 6 sources of matrix for non-MS assays.
    For MS assays determine MFs in 6 sources if the nonisotopically labeled
    IS is used. If isotopically labeled IS is used, demonstrate that IS-normalized
    MF is close to unity.
Validation batches Analyze at least 3 batches for accuracy and precision. At least 1 validation batch
    should be made as large as the largest anticipated sample analysis batch.
QC samples Concentration of QC samples should be:
    Low QC: About 3 times the LLOQ
    Mid QC: Middle of the range (at about the geometric mean of low and high QC concentration)
    High QC: Near the high end of the range, ~70% to 85% of ULOQ
    Dilution QC: Suffi cient to cover highest anticipated dilution
QC acceptance criteria Intra- and inter-batch precision (%CV) and accuracy (%RE) should be:
    QCs prepared at all concentrations greater than LLOQ ≤15%;
    QC prepared at LLOQ concentration ≤20%
Calibration standards Include the following calibration standards with each batch:
    Minimum of 6 non-zero standards
    Matrix blank: Matrix sample without internal standard
    Zero standard: Matrix sample with internal standard
Standard acceptance criteria Acceptance criteria for calibration standards are:
    LLOQ standard ≤20%
    All other standards ≤15%
    At least 75% of standards should meet above criteria
Matrix blank Interference in matrix blank should be ≤20% of LLOQ response
Recovery Extent of recovery of analyte and IS should be consistent, precise, and reproducible.
    Determine recovery at 3 concentration levels.
Stability Perform the following stability experiments:
    Stock solution: Minimum of 6 hours at room temperature
    Postpreparative (extracted samples/autosampler tray):
    Longest time from preparation through sample analysis. Assess against fresh standards,
    except for autosampler reinjection reproducibility.
    Benchtop: Stability at ambient temperature (or temperature used for processing of samples)
    to cover the duration of time taken to extract the samples (typically ~4-24 hours).
    Freeze-thaw: QC samples at minimum of 2 concentrations, 3 cycles, completely thawed,
    refrozen at least 12 hours between cycles, at anticipated temperature of sample storage.
    Long-term: Cover longest time from collection to fi nal analysis for any sample in study.
    Analyze 3 aliquots at low and high concentrations with fresh standard curves and compare
    against intended (nominal) concentrations. Long-term stability can be completed
    postvalidation.
*MS indicates mass spectrometry; MF, matrix factor; IS, internal standard; QC, quality control; LLOQ, lower limit of quantitation; ULOQ, upper
limit of quantitation; CV, coefficient of variation; and RE, relative error.
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1.2.3.1.   Biological sample preparation 
 
Biological sample preparation begins first with spiking the analyte in the 
biological matrix. Analyte spiking is not a trivial matter, as the goal is to 
replicate the incurred samples (samples from a dosed human or animal) 
as much as possible. As standard solutions are usually prepared in 
organic solvent, it is advisable to limit their volume in the biomatrix 
calibrators and quality controls to less than 5%. Not only does this avoid 
unnecessary dilution of the biomatrix before extraction and analysis, this 
low percentage will not cause precipitation of the protein constituents 
while ensuring reproducible extractions. 
 
There are four common sample preparation methods: solid phase 
extraction, liquid-liquid extraction, deproteinization, and simple dilution 
(usually reserved for low protein samples like urine). 
 
1.2.3.1.1. Solid phase extraction 
 
Solid phase extraction (SPE) is a technique to isolate the analyte of 
interest from the biomatrix that is similar to liquid chromatography. The 
packing, or sorbents, used are silica and polymeric-based with ligands of 
C8, C18, IEX (cation exchange and anion exchange), phenyl, and 
  50 
versatile mixed-mode sorbents like the hydrophobic and hydrophilic 
mixture, HLB [32]. 
The general protocol for SPE involves conditioning the sorbant with 100% 
organic (usually methanol), conditioning with water or buffer, loading the 
sample (usually diluted with water or buffer), rinsing away the other matrix 
components, and finally elution. Paramount considerations are pH loading 
and organic percentage at washing and elution (figure 1.22). These steps 
are dependent on the analyte chemical properties and the mode of 
extraction chosen. 
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1.22, Illustration of SPE 
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1.2.3.1.2. Liquid-liquid extraction 
 
Liquid-liquid extraction (LLE) is a fast and useful procedure to separate 
analytes from matrix based on their differential partitioning into solvents 
[33]. Solvents that are not miscible with aqueous solution are used, and 
the analyte partitions into the solvent based on their distribution into the 
organic versus the aqueous phase. 
Table 1.4 lists common solvents and their densities and boiling points. 
Considering the density of water (and ergo the biomatrix) is 1, any solvent 
with a density <1 will settle above the matrix and facilitate easy removal. 
The partition coefficient refers to a ratio of concentration of solubility of 
analyte between the two phases: 
 
         (15) 
 
Most analytes have an order of magnitude higher solubility (Kd) in organic 
over aqueous. If the analyte is ionized at physiological conditions, pH 
manipulation may be utilized to form a non-charged species. Still, 
incomplete extraction is expected as extraction is based on equilibrium. 
The fraction of analyte that remains in the aqueous phase after one 
extraction can be calculated by the following equation, 
  
Kd =
[A]organic
[A]aqueous
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     (16) 
 
Where V = volume in mL. 
 
As is evident by the above equation, it is often necessary to perform more 
than one LLE to achieve acceptable extraction recoveries of the analyte 
from the biomatrix as there is always a small amount of analyte that will 
be left in the aqueous phase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
moleAX
moleAY
= mole fraction, f = VaqueousVaqueous + KdVorganic
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Table 1.4, Properties of some common solvents for LLE under conditions 
of standard temperature and pressure. 
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1.2.3.1.2.1. Salting-out assisted liquid-liquid extraction 
 
LLE is a great extraction method for analytes that are either not charged 
at physiological pH, or compounds with chemical characteristics that make 
them amenable to pH manipulation for differential extraction. Very polar 
compounds may be subjected to a different kind of LLE using solvents 
that are miscible with the aqueous phase. Adding salts to the aqueous 
phase before the addition of miscible solvents facilitates phase separation 
[34]. Appropriate salts include ammonium sulfate, ammonium formate, and 
ammonium acetate. Adding these salts will facilitate the phase separation 
of common solvents such as isopropanol and acetonitrile [35]. 
 
1.2.3.1.3. Deproteinization 
 
One of the most convenient methods of sample preparation is 
deproteinization by organic solvents. The addition of sufficient percentage 
(>50%) of organic solvents such as methanol and acetonitrile influence 
proteins to associate with each other and effectively fall out of solution 
[36]. Although this method of sample preparation is fast and inexpensive, 
one drawback is that higher concentrations of residual salts are left in the 
extracted portion and can lead to unwanted matrix effects. 
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1.2.3.2.   Matrix effect 
 
An essential evaluation for method development is the consideration and 
calculation of matrix effects. Matrix effects are defined as the measure of 
enhancement or suppression of analyte in extracted matrix compared to 
analyte in solution (equation 17). 
 
    (17) 
 
A calculation of 1 indicates no matrix effects, where <1 indicates 
suppression and >1, enhancement. 
 
As mentioned in section 1.2.2.1, the ionization technique can have a great 
effect on matrix effects. Additionally, the extraction method plays an 
important role in eliminating as many of the interfering components as 
possible. Other tactics to improve matrix effects include changes in the 
chromatographic separation and the utilization of internal standard. 
Internal standards are added to the sample before extraction and used in 
the quantitative calculations. For example, the matrix effect calculation in 
the presence of an internal standard is: 
 
matrix effect = response of analyte in extracted matrixresponse of analyte in solution
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    (18) 
 
As is evident by equation 18, the division of the response of analyte by 
the response of the internal standard can help to eliminate errors by 
extraction and injection. Further, choosing an internal standard the elutes 
at the same retention time as the analyte ensure that both compounds 
experience the same matrix enhancement or suppression and hence that 
deviation can be mathematically eliminated from the quantitation [37]. 
 
1.3.    Conclusion 
 
Careful consideration in the choice of analytical instrumentation, 
separation, and extraction method can determine the success of 
bioanalytical method development. Understanding the chemical properties 
of the analyte(s) of interest as well as the instrumental and HPLC theory 
help to ensure that if a roadblock is met, it can be overcome with a new 
approach. 
  
Matrix Effect = 
response of analyte in extracted matrix
response of internal standard in extracted matrix
⎛
⎝⎜
⎞
⎠⎟
response of analyte in neat solution
response of internal standard in neat solution
⎛
⎝⎜
⎞
⎠⎟
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CHAPTER II 
 
 
DETERMINATION OF HEXAMTHYLENE BISACETAMIDE, AN 
ANTINEOPLASTIC COMPOUND, IN MOUSE AND HUMAN PLASMA AND 
MOUSE MAMMARY TUMOR BY LC–MS/MS 
 
2.1.  Introduction 
 
Hexamethylene bisacetamide (HMBA) is a hybrid bipolar compound first 
synthesized and characterized as an erythroid differentiator for murine 
erythroleukemic cells (MELC) in 1976 [1]. Initially inspired by the 
structures and functions of DMSO and N-methylacetamide, HMBA was 
used as the model differentiating agent for a class compounds known as 
acetylated diamines.  At a concentration of 5 mM, HMBA caused > 99% of 
MELC in culture to differentiate without cytotoxicity [1].  Furthermore, 
experimentation showed that HMBA also induced terminal differentiation 
in a variety of leukemic cell lines [2, 10].  Based on these findings, HMBA 
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was studied in several Phase I and Phase II clinical trials for the treatment 
of myelodysplastic syndrome (MDS), acute myelogenous leukemia (AML), 
general advanced cancer, and solid tumors [3-9]. Pharmacokinetic studies 
of HMBA in humans revealed a relatively short half-life of 2.4 – 2.9 hours 
[24] (figure 2.1). Serious side effects of HMBA, such as thrombocytopenia, 
limited the dose escalation and prevented sufficient plasma 
concentrations to be realized for its terminal differentiating potential. 
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Figure 2.1, Pharmacokinetic properties of HMBA in humans. 
 
 
 
 
 
 
 
Human  
t½, hour 2.4-2.9 
Vd, L/m2 1.1 – 30.2 (4 – 21%) 
Max tolerated (humans) , (g/m2)/day 33.6 
Highest plasma concentration, mM 1.5-2 
Clearance (total body), (mL/min)/m2 61-82 
Renal Clearance % 40-45% 
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Recent studies show that HMBA induced the expression of an 
endogenous protein, hexamethylene bisacetamide inducible protein 1 
(HEXIM1), which inhibits cell growth [11, 12]. Increased HEXIM1 
expression in breast tumor and breast epithelial cells resulted in a 
decrease of cell proliferation [12]. Additionally, not only did HEXIM1 inhibit 
cell proliferation, it interacted with the estrogen-receptor (ER)-gene 
transcription complex and prevented mammary gland development in vivo 
[13].  Such properties indicated a possible new role for HMBA in the 
treatment of breast cancer.  It has been proposed that HEXIM1 interferes 
with kinase action at the coding region of ER-responsive genes preventing 
the phosphorylation of RNA polymerase II (RNAP II) by the kinase 
complex, positive transcriptional elongation factor b (P-TEFb) [13, 14].  
Phosphorylation of RNAP II by P-TEFb facilitates complete mRNA 
elongation [15].  The prevention of this phosphorylation commits the cell 
to the abortive phase of elongation, and halts transcription [16] (figure 2.2). 
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Figure 2.2, Graphic of the antiproliferative action of HEXIM1. 
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To support studies of HMBA at lower doses as a potential therapeutic 
agent for breast cancer, a sensitive analytical method is required.  Up to 
date, the published analytical methods for the measurement of HMBA in 
plasma and urine are LC-UV and GC-N/P based methods, which have 
lower limits of quantitation (LLOQs) of 1.00 µg/mL and 2.00 µg/mL, 
respectively [17, 18]. These and other methods have been applied to 
several high-dose HMBA Phase I and II clinical trials [3-9, 19, 20], but the 
LLOQs of these methods are not sufficient for the measurement of HMBA 
in the majority of biological samples for breast cancer study with 
concentrations less than 1.00 µg/mL.  This paper describes, for the first 
time, the development and validation of an LC-MS/MS method for the 
quantitative measurement of HMBA in both mouse and human plasma and 
mouse mammary tumor homogenate with an LLOQ of 0.500 ng/mL and a 
linear calibration range up to 100 ng/mL.  To circumvent the toxic effects 
of HMBA, directed dosing using the FDA approved polymer poly(lactic-co-
glycolic) acid is used. In this work, heptamethylene bisacetamide (7MBA) 
was used as the internal standard.  Both HMBA and 7MBA were 
recovered from biological matrices by a simple step of deproteinization 
with acetonitrile.  Separation of the analyte and internal standard was 
achieved on a Waters Atlantis® T3 column using 15% acetonitrile 85% 10 
mM ammonium acetate, pH 4.0 as mobile phase.  Quantitation was 
carried out by tandem mass spectrometry operated in the positive 
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multiple-reaction-monitoring (MRM) mode.  Finally, the validated method 
was applied to the measurement of HMBA concentrations in two 
preliminary mouse studies. 
 
2.2.  Materials and methods 
 
2.2.1 Chemicals and standard solutions 
 
Ammonium acetate and hexamethylene bisacetamide (catalog no. 224235) 
were from Sigma-Aldrich (St. Louis, MO, USA).  HPLC-grade acetonitrile 
was from Pharmco-AAPER (Louisville, KY, USA). HPLC-grade glacial 
acetic acid was from J.T. Baker through VWR (West Chester, PA, USA). 
Sodium chloride, sodium hydrogen phosphate, potassium dihydrogen 
phosphate, sodium chloride, potassium chloride, 2,2,2-tribromoethanol, 
and tert-amyl alcohol were from Fisher Scientific (Pittsburgh, PA, USA). 
Heptamethylene bisacetamide (7MBA) was obtained from the DTP Open 
Chemical Repository of the US National Cancer Institute 
(http://dtp.cancer.gov) with assigned code NSC36911.  Six pooled blank 
human plasmas with specific lot numbers (W06509203366, 
W06509105961, W069509203227, W069509203370, W069509203365, 
and W069509203234) were from Haemtech, Inc (Essex Junction, Vermont, 
USA), which were donated by Dr. Michael Kalafatis at Cleveland State 
University.  Six pooled blank mouse plasmas (citrated) with specified lot 
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numbers (09F21004, 11B21080, 11B21081, 11B21082, 11B21083, and 
11B21084) were purchased from Lampire Biological Laboratories 
(Pipersville, PA, USA). The Type 1 deionized water was obtained from a 
Barnstead NANOpure® water purification system (Thermo Scientific, 
Waltham, MA, USA). 
 
The mobile phase for liquid chromatographic separation was prepared by 
mixing acetonitrile and 10 mM ammonium acetate (pH 4.0) at a ratio of 
15:85 (v/v).  The standard stock solutions of HMBA and 7MBA were 
prepared in acetonitrile at a concentration of 1 mg/mL. The standard 
working solutions of HMBA at concentrations 50.0, 100, 150, 500, 1.00 x 
103, 3.00 x 103, 5.00 x 103, 9.00 x 103, and 10.0 x 103 ng/mL for the 
plasma studies and at 10.0, 20.0, 100, 200, 1.00 x 103, 2.00 x 103, 30.0, 
600, and 1.80 x 103 ng/mL for tissue study were prepared by serial 
dilutions of the standard stock solution of HMBA with the mobile phase.  
The internal standard working solution of 100 ng/mL was prepared by two 
subsequent dilutions (1:100) of the standard stock solution of 7MBA in the 
mobile phase. The standard stock solutions were kept in amber glass vials 
and stored at -20°C. 
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2.2.2.  Liquid chromatography tandem mass spectrometry 
 
The liquid chromatography tandem mass spectrometry system was 
comprised of a AB Sciex QTrap® 5500 mass spectrometer equipped with 
electrospray ionization (ESI) probe and syringe pump (AB Sciex, Foster 
City, CA, USA), and a Shimadzu Prominence UFLC system with binary 
pump and autosampler (Shimadzu, Columbia, MD, USA).  The system was 
connected using PEEK tubing (1/16 in. o.d. x 0.01 in. i.d.).  Data was 
acquired and processed using AB Sciex Analyst software (version 1.5.1). 
 
Analytical separation of HMBA and the IS was performed isocratically at 
ambient temperature on a Waters Atlantis® T3 (3 µm, 120 Å, 2.1 x 50 mm) 
column (Waters, Milford, MA, USA) with the mobile phase at the flow rate 
of 0.150 mL/min.  The injection volume of each sample was 5 µL.  Prior to 
initial sample injection, the column was equilibrated with the mobile phase 
at the above flow rate for a minimum of 15 min. 
 
The AB Sciex QTrap® 5500 mass spectrometer was operated by the 
positive electrospray ionization (ESI) mode using the following instrument 
settings: CUR 34; CAD HIGH; IS 4500; TEM 550; GS1 38; GS2 32; DP 70; 
EP 10; CE 20; CXP 16. These settings were optimized first by direct 
infusion of 200 ng/mL each HMBA and the IS at 10 µL/min using the 
integrated syringe pump, then refined by the “Compound Optimization” 
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feature of the Analyst software using flow injection analysis.  HMBA and 
the IS were quantitated by MRM mode using the following mass 
transitions: m/z 201.2 à 159.2 for HMBA and m/z 215.2 à 173.2 for 
7MBA, with a dwell time of 300 ms for each analyte. 
 
2.2.3.  Preparation of plasma calibrators and quality controls 
 
Plasma calibrators and quality controls (QCs) were prepared using the 
pooled blank human and mouse plasmas and mouse mammary tumor 
tissue homogenate which contained no detectable HMBA.  Tumor tissue 
was homogenized with 1x PBS to 0.4 mg/mL for approximately 2 minutes 
on ice using a handheld polytron homogenizer. The homogenizer was 
rinsed between each sample with fresh methanol followed by 1x PBS. 
Plasma calibrators were prepared by addition of 10 µL of the mobile 
phase (for the blank of HMBA) or each standard working solution of HMBA 
to 990 µL of blank pooled plasma. Tumor homogenate calibrators were 
prepared by the addition of 5 µL of the mobile phase (for the blank of 
HMBA) or each standard working solution of HMBA to 95 µL of blank 
tumor homogenate. These preparations made final concentrations of 0.00, 
0.500, 1.00, 5.00, 10.0, 50.0, and 100 ng/mL each in a 1.5-mL 
microcentrifuge tube (VWR, West Chester, PA, USA).  Plasma QCs were 
prepared by addition of 10 µL of each standard working solution of HMBA 
to 990 µL of blank pooled plasma where tumor homogenate QCs were 
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prepared by the addition of 5 µL of each standard working solution to 95 
µL blank tumor homogenate to make final concentrations of 1.50, 30.0, 
and 90.0 ng/mL each in a 1.5-mL microcentrifuge tube.  The calibrators 
and QCs were vortex-mixed for 30 s, and then stored overnight at -20°C 
before use.. 
 
2.2.4.  Animal study 
 
The animal study protocol for this work was approved by the Institutional 
Animal Care and Use Committee at Case Western Reserve University. 
FVB mice from Jackson Laboratories (Bar Harbor, ME, USA). The mouse 
model of human breast cancer, FVB - MMTV/HEXIM1/PyMT, was 
generated by crossing MMTV/HEXIM1 mice [13] with PyMT transgenic 
mice [unpublished data]. Treatment regimens were started at 4 – 6 weeks 
of age. For investigation, the mice were anesthetized using Avertin 
(containing 1.3% tribromoethanol and 0.8% tert-amyl alcohol).   HMBA 
concentrations in plasma and mammary tumor tissue were investigated 
two ways: by direct injection (10 mg/kg) in saline (0.9% sodium chloride in 
water) and by injection of 2 mg/kg (to 0.05 cc) of 5 mM HMBA-loaded 
PLGA each into the left thoracic mammary gland through the nipple.  At 0 
(pre-dose), 15, 30, 45, 60, 120, 240, 360, and 480 min, the mice were 
ocularly bled and then sacrificed.  Blood samples were collected in sterile 
1.5-mL microcentrifuge tubes and centrifuged at 3000 x g for 15 min.  
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Tumor samples were weighed and homogenized with 1x PBS to 0.4 
mg/mL. Mouse plasma and tumor homogenate samples were stored at -
20°C until analysis.  The developed LC/MS method was used to determine 
the concentrations of HMBA in mouse plasma over the time course of 
study. 
 
2.2.5.  Sample preparation 
 
Plasma and tumor homogenate calibrators and QCs, as well as mouse 
plasma and tumor homogenate samples from FVB mice, were prepared as 
follows: samples were removed from -20°C freezer, and thawed to room 
temperature; for each plasma sample, 25 µL of plasma together with 5 µL 
of the IS working solution (100 ng/mL) or the mobile phase (for the blank 
of IS) were added to 1.5-mL microcentrifuge tube, vortex-mixed for 30 s, 
and kept at 4°C for 30 min; the sample was then deproteinized with 100 
µL of HPLC-grade acetonitrile at a ratio of 3.3 to 1 by vortex-mixing for 30 
s; following centrifugation at 24,400 x g for 10 min, the supernatant was 
pipetted into a 1.5-mL microcentrifuge tube and dried in a Savant DNA120 
SpeedVac® concentrator (Thermo Scientific, Asheville, NC, USA) at 43°C 
for 30 min; finally, the resultant residual was reconstituted in 25 µL of the 
mobile phase for the subsequent LC-MS/MS analysis. 
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2.2.6.  Stability studies 
 
The stability of HMBA in human and mouse plasma before and after 
sample preparation, and through freeze-and-thaw cycles were 
investigated at low, medium, and high QC concentrations.  These studies 
included QC samples kept on bench top at 22°C for 0, 4, 8, and 24 h 
before sample preparation and analyses, QC samples kept in autosampler 
at 4°C for 0, 4, 8, and 24 h after sample preparation and before LC-
MS/MS analyses, and QC samples undergone three freeze-and-thaw 
cycles where the samples were frozen at −20°C for at least 24 h and 
thawed at room temperature unassisted 3 times.   
 
2.3. Results 
 
2.3.1. LC–MS/MS 
 
Due to its chemical structure, HMBA has a propensity to interact with the 
particle substrate of the bonded phase resulting in a tailing peak. 
Therefore, columns with endcapping (e.g., Waters XBridgeTM C8, Waters 
XTerra® C8, and Waters Atlantis® T3) were considered for analytical 
separation.  Among the columns tested, Waters Atlantis® T3 (2.1 x 50 mm, 
3 µm) displayed not only excellent retention times and reproducibility for 
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the analytes, but also symmetrical peak shapes without adding additional 
modifiers to the mobile phase.  Therefore, it was chosen for this work. 
 
Full-scan infusion analysis revealed [M+Na]+ as the predominant 
precursor ion in the aqueous solutions of both HMBA and the IS (mass 
spectra not shown).  The addition of an ammonium salt was effective to 
suppress the formation of [M+Na]+ and produce [M+H]+ as the major 
precursor ions. After investigation with each ammonium acetate and 
ammonium formate, it was determined that the former resulted in greater 
detection signal; therefore, ammonium acetate was added to the mobile 
phase in the subsequent studies.  Precursor ions [HMBA+H]+ at m/z 201.2 
and [IS+H]+ at m/z 215.2 produced major product ions at m/z 159.2 and 
m/z 173.2 by breaking the amide bond (Figure 2.3). Therefore, the mass 
transitions of m/z 201.2 à 159.2 for HMBA and m/z 215.2 à 173.2 for the 
IS were used for the quantitation of HMBA by tandem mass spectrometry 
with MRM mode. 
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Figure 2.3, Product ion spectra and structures of (A) HMBA and (B) 7MBA, 
the internal standard (IS). 
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2.3.2. Matrix interference and specificity 
 
The use of Waters Atlantis® T3 (2.1 x 50 mm) as analytical column for 
separation and 35% methanol and 5 mM ammonium acetate (pH 6.8) as 
mobile phase was first evaluated.  While achieving excellent retention and 
separation for HMBA and the IS, interferences were encountered in both 
plasma matrices, more severely in mouse plasma (chromatograms not 
shown).  This unidentified endogenous compound co-eluted and produced 
a common product ion of m/z 159.2 with HMBA in the tandem mass 
spectrometer.  
 
Since choosing a different product ion for quantitation of HMBA reduced 
the sensitivity of detection significantly, other approaches to minimize the 
interference were examined: (i) various sample preparation methods, such 
as (a) protein precipitation using various volume ratio of plasma to organic 
solvent(s) [i.e., plasma to acetonitrile ratio of 1:2, 1:3, 1:4, and 1:5 with 
and without 0.1% formic acid or 0.1% ammonium hydroxide modifiers; 
plasma to acetonitrile/methanol (75/25) ratio of 1:5, as well as plasma to 
acetonitrile/ethanol (75/25) ratio of 1:5], (b) liquid-liquid extraction with 
saturated ammonium sulfate and 15/85 isopropanol/ethyl acetate [21], and 
(c) denaturation of plasma proteins by heating the sample at 100°C for 5 
min prior to centrifugation; (ii) separation by different types of column [e.g., 
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Waters XBridge™ C8 (2.1 x 50 mm, 3 µm, 120 Å) and Waters XTerra® C8 
(2.1 x 50 mm, 3 µm, 120 Å)]; and (iii) changing mobile phase composition 
and/or pH.  
 
All sample preparation methods tested yielded similar results except 
liquid-liquid extraction with saturated ammonium sulfate and 15/85 
isopropanol/ethyl acetate, which worsened the interference.  Among the 
columns examined, the Waters Atlantis® T3 (2.1 x 50 mm) column 
displayed the best chromatographic performance.  The most satisfactory 
results were obtained by changing the mobile phase organic composition 
and pH (i.e., 15% acetonitrile, 85% 10 mM ammonium acetate at pH 4.0) 
for both human and mouse plasma.  
 
Finally, the optimal separation of HMBA and the IS was achieved on a 
Waters Atlantis® T3 (2.1 x 50 mm) column at 2.2 and 3.7 minutes by a 
mobile phase containing 15% acetonitrile, 85% 10 mM ammonium acetate 
at pH 4.0 using 3.3 volumes of acetonitrile for deproteinization. Under 
these conditions, the previously co-eluted interference was completely 
resolved from human plasma (Figures 2.4A and 2.4B).  Even though the 
interfering compound in mouse plasma and tissue homogenate was not 
completely removed (Figure 2.4C and 2.4E, top traces), it had been 
reduced to a minimum that was insignificant for the analysis.  The peak 
area of the interference in mouse plasma was about 8% and homogenate 
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was 14% of the LLOQ for HMBA by the LC-MS/MS method (Figure 2.4C-
F), an acceptable level by the industry [22].  The specificity of the LC-
MS/MS method was further demonstrated by measuring HMBA at the 
LLOQ (0.500 ng/mL) of the method from six lots of human plasma 
samples and six lots of mouse plasma samples (see Section 2.3.3.2.)   
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Figure 2.4, Representative MRM chromatograms of human plasma: (A) 
double blank and (B) 0.500 ng/mL HMBA (LLOQ), 20 ng/mL IS, mouse 
plasma: (C) double blank and (D) 0.500 ng/mL HMBA, 20 ng/mL IS, and 
tumor homogenate: (E) double blank and (F) 0.500 ng/mL HMBA, 20 
ng/mL IS. 
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2.3.3.  Method validation 
 
The method was fully validated following the guidelines brought forth by 
the FDA’s Bioanalytical Method Validation Guidance for Industry [22, 23] 
for both plasmas, and fit-for-purpose for tumor homogenate.  
 
2.3.3.1. Recovery and matrix factor 
 
Recovery was calculated by comparing the mean-peak-area ratios of 
HMBA to the IS of corresponding QC samples prepared by spiking the 
analytes to matrix before and after deproteinization.  Matrix factor was 
calculated by comparing the mean-peak-area ratios of HMBA to the IS in 
the QC samples prepared by spiking the analytes after deproteinization to 
those prepared in the mobile phase.  For these studies, triplicate 
measurements were performed for all low, medium, and high QC 
concentrations.  
 
Table 2.1 shows that the recoveries of HMBA were consistent and 
between 96% and 98% in human plasma, 97% and 102% in mouse 
plasma, and 100% and 108% in tumor homogenate over the three 
concentrations examined.  Deproteinization by 3.3 volumes of acetonitrile 
was sufficient to recover HMBA from the matrices.    
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Matrix factor is a measure of sample matrix effect (either suppression or 
enhancement) on analytical signal of HMBA.  In this work, matrix factor for 
the matrices ranged 0.93 - 1.02 (Table 2.1), which indicated that the 
matrix effect was in the magnitude of -7% to 2% (< ±15%).  Hence, the 
matrix suppression or enhancement of the analytical signals was not 
significant and could be neglected without further correction. 
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Table 2.1, Recovery and matrix factor of HMBA in human and mouse 
plasmas and mouse tumor homogenate. 
 
 
  
Human 1.50 0.053 ± 0.001 0.055 ± 0.001 0.054 ± 0.001 96 ± 1 1.02 ± 0.03
30.0 1.04 ± 0.003 1.05 ± 0.01 1.05 ± 0.01 99 ± 1 1.00 ± 0.01
90.0 2.92 ± 0.01 3.01 ± 0.02 2.95 ± 0.02 98 ± 0.2 1.02 ± 0.01
Mouse 1.50 0.050 ± 0.001 0.049 ± 0.001 0.051 ± 0.002 102 ± 1 0.96 ± 0.03
30.0 0.94 ± 0.002 0.97 ± 0.04 0.96 ± 0.01 97 ± 4 1.01 ± 0.01
90.0 2.66 ± 0.004 2.68 ± 0.02 2.70 ± 0.03 99 ± 1 0.99 ± 0.01
Tumor 1.50 0.056 ± 0.001 0.056 ± 0.002 0.058 ± 0.001 100 ± 2 0.97 ± 0.05
Homogenate 30.0 0.96 ± 0.003 0.92 ± 0.02 0.98 ± 0.02 104 ± 1 0.94 ± 0.04
90.0 2.81 ± 0.01 2.61 ± 0.06 2.82 ± 0.03 108 ± 3 0.93 ± 0.04
n = 3
a Recovery  = [(mean area ratio of HMBA to IS extracted) /(mean area ratio of HMBA to IS spike 
b Matrix Factor (MF)  = [(mean area ratio of HMBA to IS spike after extraction) / (mean area ratio 
of HMBA to IS in mobile phase)]
Nominal 
[HMBA] 
(ng/mL)
AHMBA/AIS 
extracted ± SD
AHMBA/AIS 
spike after 
extraction ± 
SD
AHMBA/AIS in 
mobile phase 
± SD
Recoverya 
± SD (%) MF
b ± SD 
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2.3.3.2.  Calibration curve and lower limit of calibration 
 
The linear calibration ranges of 0.500-100 ng/mL were established for 
HMBA in both human and mouse plasma and tumor homogenate with 
internal standard using six non-zero calibrators, a single-blank (IS only), 
and a double-blank.  The calibration equations derived from seven 
individual calibration curves on three different days with 1/x weighting 
were y = 0.0287(±0.0046) x + 0.084(±0.0043), r2 = 1.00 for human plasma, 
y = 0.0294(±0.0030) x + 0.0118(±0.0057), r2 = 0.999 for mouse plasma, 
and y = 0.0272(±0.0045) x + 0.008(±0.004), r2 = 0.999 for tumor 
homogenate. The accuracy and precision of each individual calibrator are 
summarized in Table 2.2, were ≤ ±3% and ≤ 6% in both human and mouse 
plasma.  
  
The LLOQ of the method was defined by the lowest calibrator (0.500 
ng/mL) of the calibration curve, which was confirmed by measuring HMBA 
from six lots of human plasma samples and six lots of mouse plasma 
samples.  The precision and accuracy of each lot of plasma at LLOQ were 
calculated based on five separate samples with one injection per sample.  
The data are summarized in Table 2.3.  The accuracy and the precision of 
the method at the LLOQ were ≤ ±8% and ≤ 3% in human plasma, ≤±6% 
and ≤9% in mouse plasma, and ≤ ±8% and ≤ 4% in tumor homogenate, 
respectively. 
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Table 2.2, Accuracy and precision of plasma and tumor homogenate 
calibrators 
 
 
 
 
 
 
Human 
Plasma
Mouse 
Plasma
Tissue 
Homogenate
Human 
Plasma
Mouse 
Plasma
Tissue 
Homogenate
0.500 1 1 -8 3 6 4
1.00 -1 3 2 2 2 1
5.00 -0.5 -3 1 3 2 2
10.0 2 -2 5 4 5 1
50.0 -3 2 1 2 3 2
100. 1 -0.6 -1 2 1 1
Nominal 
[HMBA] 
(ng/mL)
Accuracy (%E)a Precision (%CV)b
b %CV = (standard deviation / mean value) x100%
a %E = {(measured [HMBA] - nominal [HMBA]) / nominal [HMBA]} x100%
n = 7, over three different days
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Table 2.3, HMBA at LLOQ in six different lots of human and mouse 
plasma. 
  
Lot A Lot B Lot C Lot D Lot E Lot F
Nominal 
[HMBA] 
(ng/mL)
0.5 0.5 0.5 0.5 0.5 0.5
Human Mean 0.525 0.502 0.491 0.463 0.461 0.472
(n = 5) Standard Dev. 0.01 0.004 0.014 0.002 0.004 0.006
Accuracy (%E) 5 0.3 -2 -7 -8 -6
Precision (%CV) 2 1 3 0.5 1 1
Mouse Mean 0.528 0.486 0.498 0.489 0.475 0.497
(n = 5) Standard Dev. 0.013 0.043 0.031 0.035 0.01 0.028
Accuracy (%E) 6 -3 -0.3 -2 -5 -1
Precision (%CV) 3 9 6 7 2 6
Each datum point calculated by five parallel measurements from five identical QCs
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2.3.3.3. Precision, accuracy, and dilution studies 
 
Inter-assay precision and accuracy were assessed by five parallel 
injections from five identical QC samples at each concentration over three 
separate days of analysis.  Intra-assay precision and accuracy were 
assessed by five parallel injections from five identical QC samples at each 
concentration.  Accuracy was expressed as percent relative error (%E), 
and precision was determined as percent standard deviation or coefficient 
of variation (%CV).  As shown in Table 2.4, the intra- and inter assay 
accuracy and precision were ≤ ± 9% and ≤ 10% for both human and 
mouse plasmas.  
 
Since the upper limits of the linear calibrations curve were 100 ng/mL, 
sample concentrations beyond these concentrations were subject to 
dilution studies.   In this work, dilution effect was assessed by 1:100 
dilution of plasma QCs at the concentrations of 150, 3.00 x 103, and 9.00 
x 103 ng/mL by the pooled blank plasma, with the data summarized in 
Table 5.  As shown in the table, the dilution study had an accuracy of ≤ 
±10% and precision of ≤ 3% over the concentration range studied.  These 
results indicated that dilution of plasma samples which had concentrations 
beyond the upper limit of the calibration curve would not produce 
significant error in the measurement of actual HMBA concentrations. 
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Table 2.4, Summary of intra- and inter- accuracy and precision in human 
and mouse plasmas and tumor homogenate. 
 
 
 
 
 
 
Intra-run Inter-run
Human 1.50 1.59 ± 0.03 6 2 1.46 ± 0.14 -3 10
30.0 31.2 ± 0.6 4 2 29.5 ± 1.6 -2 6
90.0 87 ± 3 -3 3 82 ± 4 -9 5
Mouse 1.50 1.60 ± 0.02 7 1 1.44 ± 0.14 -4 10
30.0 31.6 ± 0.8 5 2 32.1 ± 1.1 7 3
90.0 94 ± 1 4 1 94 ± 4 4 4
Tumor 1.50 1.52 ± 0.04 1 4
Homogenate 30.0 30.0 ± 0.8 0 3
90.0 88 ± 2 -2 3
b Each datum point calculated by five parallel measurements from five identical QCs of three different days.
Nominal 
[HMBA] 
(ng/mL)
Measured 
[HMBA] a 
± SD 
(ng/mL)
Measured 
[HMBA] b 
± SD 
(ng/mL)
a Each datum point calculated by five parallel measurements from five identical QCs.
Accuracy 
(%E)
Precision 
(%CV)
Accuracy 
(%E)
Precision 
(%CV)
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Table 2.5, Summary of dilution studies in human and mouse plasmas. 
  
Initial 
[HMBA] 
(ng/mL)
Dilution 
Factor
Nominal 
[HMBA] 
(ng/mL)
Measured 
[HMBA] ± 
SD 
(ng/mL)
Accuracy 
(%E)
Precision 
(%CV)
Actual 
[HMBA] 
(ng/mL)
Human 150 100 1.50 1.51 ± 0.05 1 3 151
(n = 3) 3.00 x103 100 30.0 29.2 ± 0.2 -3 1 2.92 x103
9.00 x103 100 90.0 92.9 ± 1.0 3 1 9.29 x103
Mouse 150 100 1.50 1.52 ± 0.04 1 3 152
(n = 3) 3.00 x103 100 30.0 31.9 ± 0.8 6 2 3.19 x103
9.00 x103 100 90.0 98.9 ± 1.6 10 2 9.89 x103
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2.3.3.4. Stability 
 
The stability of HMBA was determined by comparing the mean-peak-area 
ratios of HMBA to the IS in the QC samples to those of freshly prepared 
QCs, expressed in terms of recovery.  As shown in Table 6, the recoveries 
of QC samples were 98-106%, 97-107%, and 91-103% for the bench top, 
the autosampler, and the freeze-and-thaw studies, respectively.  These 
studies indicated that there was no significant deviation in the quantitation 
of HMBA under the experimental conditions. 
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Table 2.6, Summary of stability of HMBA in human and mouse plasmas. 
  
4 h 8 h 24 h 3 Freeze-thaw cycles
Nominal 
[HMBA] 
(ng/mL)
Recovery ± 
SD (%)
Recovery ± 
SD (%)
Recovery ± 
SD (%)
Recovery ± 
SD (%)
Bench-top stability Human 1.50 101 ± 5 100 ± 5 101 ± 7 91 ± 1
(before deproteinization) 30.0 106± 4 104 ± 4 105 ± 2 100 ± 2
90.0 105 ± 3 104 ± 1 104 ± 1 103 ± 1
  
Mouse 1.50 102 ± 1 102 ± 2 103 ± 2 103 ± 2
30.0 99 ± 1 98 ± 2 99 ± 1 97 ± 0.4
90.0 100 ± 4 102 ± 4 101 ± 3 101 ± 4
Autosampler stability Human 1.50 102 ± 2 100 ± 4 107 ± 4
(after deproteinization) 30.0 102 ± 2 100 ± 3 101 ± 3
90.0 104 ± 0.1 103 ± 2 103 ± 0.3
Mouse 1.50 100 ± 3 101 ± 1 98 ± 1
30.0 100 ± 1 103 ± 1 97 ± 1
90.0 101 ± 5 103 ± 2 97 ± 3
n = 3
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2.3.4. Application to animal study 
 
The validated LC–MS/MS method was applied to the measurement of 
HMBA in FVB mice.  Due to the dose-limiting effects of HMBA 
(thrombocytopenia) and the need for millimole concentrations to elicit an 
effect, HMBA-loaded PLGA particles were developed. In this work, mouse 
plasma samples collected by the procedure described in the Section 2.2.4 
together with eight calibrators (i.e., one single-blank, one double-blank 
and six nonzero) and a set of QCs at low-, mid- and high-concentrations 
(i.e., 1.50, 30.0, 90.0 ng/mL) were thawed at room temperature.  These 
samples were prepared by the procedures described in the Section 2.2.5, 
and analyzed by the validated method.  The samples of concentrations 
beyond the upper limit of calibration curve (i.e., 100 ng/mL) were re-run by 
1:100 dilution using the pooled blank mouse plasma together with the 
dilution QC at the concentration of 9.00 x 103 ng/mL.  Figure 2.5 shows 
the HMBA concentration-time profile in FVB mice after a nipple injection of 
10 mg/kg.  Each datum point was based on duplicate measurement of a 
blood sample from a FVB mouse. To evaluate the release of HMBA from 
PLGA, mice were injected with 2 mg/kg of 5 mM HMBA-PLGA and treated 
the same as the saline model. The results of the analysis are depicted in 
figure 2.6. Additional data from two- and ten- days post injection reveal 
measurable amounts of HMBA in both tumor and plasma (table 2.7) 
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Although a higher dose of HMBA was used in these preliminary studies, 
the concentration-time profile of HMBA demonstrated not only the 
applicability of the method in its intended sample matrix, but also its 
feasibility for a wide concentration range of HMBA in plasma (from sub 
ng/mL to high µg/mL).   
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Figure 2.5, Mean concentrations of HMBA in mouse plasma over time. 
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Figure 2.6, Mean concentrations of HMBA release from PLGA in mouse 
plasma over time. 
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Table 2.7, Concentration of HMBA after injection in PLGA at two and 10 
days. 
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2.4. Conclusion 
 
This work detailed the development and validation of a LC-MS/MS method 
for the quantitation of HMBA in human and mouse plasma and mouse 
tumor tissue.  The method used a simple deproteinization step for sample 
preparation, and a reversed-phase chromatographic column for analyte 
separation.  It has a linear calibration range of 0.500-100 ng/mL and 
stability for routine analysis.  The method was successfully applied to the 
measurement of HMBA in mouse plasma samples, as well as mouse 
tumor tissue. It may be useful for the toxicokinetic study of HMBA in mice 
as well as pharmacokinetic study in humans. 
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CHAPTER III 
 
 
DEVELOPMENT OF A RAPID LIQUID CHROMATOGRAPHY TANDEM 
MASS SPECTROMETRY METHOD FOR THE ANALYTICAL 
DETERMINATION OF ILLICIT DRUGS BZP AND TFMPP IN HUMAN 
BLOOD, URINE, BILE, AND VITREOUS HUMOR 
 
3.1 Introduction 
 
Benzylpiperazine (BZP) and 1-3-trifluoromethylphenylpiperazine (TFMPP) 
are synthetic designer drugs with psychoactive properties (figure 3.1 A 
and B, respectively). BZP is a dopamine, serotonin, and noradrenalin 
agonist [1] and can also inhibit their reuptake [2]. TFMPP is a 
nonselective serotonin agonist [1]. Having structural similarity to 
amphetamine and methamphetamine (figure 3.2), early studies confirmed 
that the two drugs had similar physiological effects [3]. Additionally, 
former amphetamine addicts could not tell the difference upon their 
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administration [4]. Nowadays, BZP and TFMPP are commonly abused 
together as they have physiological effects similar to the illegal drug 3,4-
methylenedioxymethamphetamine (MDMA or ecstasy).  
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Figure 3.1, Structures of (A) Benzylpiperazine and (B) 1-3-
trifluoromethylphenylpiperazine. 
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Figure 3.2, Structural similarity of amphetamine, methamphetamine, and 
Benzylpiperazine. 
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3.1.1.  History 
 
In 1979, Hoechst-Roussel Pharmaceuticals, Inc. developed a new 
antidepressant, Befuraline (figure 3.3A), that showed promising effects in 
the treatment of depression in humans despite stimulatory side effects [5-
7]. Similarly, Trelibet (also known as Piberaline) (figure 3.3B) was 
introduced by Hungarian pharmaceutical company, Egis Pharmaceutical 
Works, in 1986 and enjoyed success until it was noted that amphetamine-
like side effects brought questions of its safety [8, 9]. It was determined 
that the effects of Trelibet (and presumably Befuraline) were 
predominantly due to its metabolite, benzylpiperazine [10]. 
Benzylpiperazine had been shown to have similar effects as amphetamine 
in two previous studies [3, 4], therefore further study as an antidepressant 
was considered a risk. The antidepressants were soon therapeutically 
abandoned. 
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Figure 3.3, Representative structures of BZP precursors A. Befuraline and 
B. Trelibet. 
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3.1.2.  Safety and legal status 
 
There are no reported fatalities due to either BZP or TFMPP alone, but 
BZP is reported to have a low seizure threshold. More importantly, the co-
administration of BZP and MDMA has resulted in sudden death most likely 
due to the drugs’ additive toxicities [11, 12].  The potential for drug mixing 
is great as they are both sold in similar-looking forms (see figure 3.4 for 
pictures taken by the U.S. DEA). 
 
As of October 2011, BZP is illegal in the USA and most countries 
worldwide with the exception of Canada. TFMPP was initially given 
emergency Schedule 1 status in the USA, but was subsequently removed 
and is no longer regulated. BZP may still be ordered online, but import 
laws restrict its delivery to countries where it is illegal. To circumvent the 
illegality of some abused drugs, individuals search the literature for 
insights into new compounds with desirable side effects that aren’t yet 
illegal [13, 14] . This practice creates the potential for an ever-changing 
arsenal of recreational drugs and reinforces the need for dynamic 
extraction, separation, and detection methods. 
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Figure 3.4, Pills seized by the U.S. DEA and testing positive for (A) MDMA 
or (B) BZP and TFMPP (http://www.justice.gov/dea/). 
  
A 
B 
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3.1.3.  Current LC-MS methods 
 
There are 4 LC/MS and 3 LC-MS/MS published methods for the screening 
[15, 16] or quantitation [17-21] of BZP and TFMPP in human plasma, 
serum, blood, and urine, with Nordgren and Beck [15] achieving the 
lowest confirmation detection limit of 0.9 ng/mL and Antia et al [17] the 
lowest limit of quantitation of 5 ng/mL. The methods use an array of 
sample extraction techniques from solid phase extraction [15, 16, 20], 
liquid-liquid extraction [19, 21] salting-out assisted liquid-liquid extraction 
[17], to simple dilution of urine [18]. Since the current work involves the 
quantitation of BZP and TFMPP in both ante- and post-mortem human 
blood, urine, bile, and vitreous humor matrices, a new extraction and LC-
MS/MS method for the two additional biomatrices is essential.  
 
3.2.  Materials and methods 
 
3.2.1 Chemicals  
 
BZP (1-Benzylpiperazine, Quik-Chek™ Drug Standard, 1 mg/mL in 
methanol, catalog no. 015813) was from Grace (Deerfield, IL, USA). 
TFMPP (1-3-Trifluoromethylphenylpiperazine hydrochloride 99%, catalog 
no. T8948), internal standard 2-MBZP (1-(2-Methylbenzyl)piperazine 97%, 
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catalog no. 644226), HPLC-grade Ammonium acetate, and ammonium 
hydroxide (28-30 wt %) were from Sigma-Aldrich (St. Louis, MO, USA).  
HPLC-grade acetonitrile (ACN) was from Pharmco-AAPER (Louisville, KY, 
USA). HPLC-grade glacial acetic acid was from J.T. Baker (Phillipsburg, 
NJ, USA). HPLC-grade Omnisolv methanol (MeOH) was from EMD 
Chemicals (West Chester, PA, USA). Pooled, drug-free hemolyzed ante- 
and post-mortem human blood was from University Hospitals, Cleveland, 
OH. Pooled, drug-free human urine was from healthy volunteers. Type 1 
deionized water was obtained from a Barnstead NANOpure® water 
purification system (Thermo Scientific, Waltham, MA, USA).  
 
3.2.2.  HPLC-MS/MS 
 
The liquid chromatography tandem mass spectrometry system consisted 
of a Shimadzu Prominence UFLC system with degasser, binary pump, and 
autosampler (Shimadzu, Columbia, MD, USA) coupled to an AB Sciex 
QTrap® 5500 mass spectrometer equipped with electrospray ionization 
(ESI) probe and integrated syringe pump (AB Sciex, Foster City, CA, 
USA). The HPLC was connected to the mass spectrometer using PEEK 
tubing (1/16 in. o.d. x 0.005 in. i.d.).  Data was acquired and processed 
using Analyst™ Software (version 1.5.1). 
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Analytical measurement of BZP, TFMPP, and 2-MBZP was achieved by 
isocratic separation on a Waters XBridge™ C6-Phenyl (3.5 µm, 130 Å, 2.1 
x 50 mm) column (Waters, Milford, MA, USA) with a flow rate of 200 
µL/min. The mobile phase used for separation was 45% 10mM ammonium 
acetate pH 5.75, 55% MeOH with an injection volume of 5 µL for each 
sample. The AB Sciex QTrap® 5500 mass spectrometer was operated in 
positive ESI mode using the following instrument settings: CUR 40; CAD 
HIGH; IS 5000; TEM 500; GS1 40; GS2 35; DP 100; EP 12; CE 29 (BZP, 
2-MBZP), 33 (TFMPP); CXP 8 (BZP, 2-MBZP), 16 (TFMPP) and a dwell 
time of 100 ms.  
 
3.2.3.  Standard solution, calibrators, dilution, and quality control sample 
preparation 
 
The standard stock solutions of TFMPP and internal standard (IS) were 
prepared to match the purchased BZP: in MeOH at 1 mg/mL. The 
standard working solutions of the BZP and TFMPP mixture at 
concentrations 50.0, 100, 150, 500, 1.00 x 103, 1.50 x 103, 5.00 x 103, 
1.00 x 104, 1.50 x 104, 2.50 x 104, and 5.00 x 104 ng/mL were prepared by 
serial dilution of the standard stock solutions with 50% ACN. The IS 
working solution was prepared by serial dilution of the standard stock 
solution of 2-MBZP to a final concentration of 500 ng/mL in 100% ACN. 
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The standard and working stock solutions were kept in amber glass vials 
and stored at -20°C.  
 
Calibration and quality control (QC) samples were prepared by spiking 
990 µL of biological matrix with 10 µL of standard working solution to final 
concentrations of 0.500, 1.00, 5.00, 10.0, 50.0, 100, 250, and 500 ng/mL 
for calibration standards and 1.50, 15.0, and 150 ng/mL for QC samples.  
 
Dilution study standards were prepared by spiking 990 µL of biological 
matrix with 5 µL of each 1 mg/mL stock solution to make 5.00 x 103 ng/mL 
or 10 µL 1.00 x 105 ng/mL standard working solution to make 500 ng/mL. 
Biological matrix calibration, QC, and dilution standards were stored in 
1.5-mL microcentrifuge tubes (VWR, West Chester, PA, USA) at -20°C 
until use. 
 
3.2.4.  Sample preparation 
 
To 100 µL of thawed biomatrix, 10 µL of IS (500 ng/mL) is added followed 
immediately by 390 µL of ACN (1:4 v/v biomatrix to ACN). The samples 
are vortex mixed for 60 s and then centrifuged for 10 min at 24400 x g. A 
100 µL aliquot of the supernatant is diluted with 100 µL water (blood 
samples) or 100 µL 10 mM ammonium acetate, pH 5.75 (urine samples) 
(1:1 v/v) in a 1.5-mL microcentrifuge tube. The diluted samples are vortex 
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mixed briefly and then transferred to limited volume polypropylene vials 
(National Scientific, Rockwood, TN, USA) for analysis.  
 
3.2.5. Dilution and concentration studies 
 
Dilution-after-extraction was performed by diluting the above extracted 
samples up to 1000 times in 50% ACN containing IS at 5 ng/mL. 
Concentration studies of blood samples was performed by first adding 10 
µL of IS (50 ng/mL) to 100 µL of thawed matrix. 390 µL of ACN is then 
added and the samples vortex mixed for 60 s followed by centrifugation 
for 10 min at 24400 x g. 80% of the supernatant is transferred to a 1.5-mL 
microcentrifuge tube and dried under 11 psi of nitrogen in a TurboVap II 
Evaporator (Zymark, Hopkinton, MA, USA) at 25°C for 40 min. The 
residual is reconstituted in 160 µL of 50% ACN for analysis. 
 
3.2.6. Validation parameters 
 
3.2.6.1. Recovery and matrix factor 
 
Recoveries were calculated by comparison of the area ratios of analyte to 
internal standard spiked before and after plasma deproteinization. Matrix 
factor was calculated by comparison of the area ratios of analyte to 
internal standard of samples in mobile phase and spiked after plasma 
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extraction. Both analyses were performed by triplicate injections at low, 
medium, and high calibrator concentrations.  
 
3.2.6.2. Precision and accuracy 
 
Intra-assay precision and accuracy was assessed by single injections of 
five separate samples at each calibrator concentration. Inter-assay 
precision and accuracy was assessed by single injections of five separate 
samples at each calibrator concentration on three different days. Accuracy 
was determined by back-calculation of the analyte to internal standard 
area ratios of the analyte detected to analyte spiked into blank plasma 
from the calibration curve. Dilution studies up to 1000 times were 
assessed by serial dilution of a 5000 ng/mL extracted sample. The dilution 
study samples were injected 3 times, and the precision and accuracy 
evaluated. The results were considered satisfactory if accuracy was ≥85% 
and precision was ±15. 
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3.2.6.3. Stability 
 
The stability of BZP and TFMPP in human blood and urine was 
determined in the matrix (pre-deproteinization), autosampler (post-
deproteinization), and through three freeze-thaw cycles at low, medium, 
and high QC concentrations. Matrix stability was investigated by 
incubating the QC samples on the bench top at 22°C for 0, 4, 8 and 24 
hours. The internal standard was added and the samples were extracted 
as above. Autosampler stability was investigated by analyzing extracted 
concentrations in the autosampler (4°C) for 0, 4, 8 and 24 hours. Freeze-
thaw stability was determined after three unassisted thaw and re-freeze 
cycles. All stability measurements were determined by comparing the 
sample analyte-to-internal standard area ratios to freshly prepared QC 
calibrators. 
 
3.2.7. Method application 
 
The validated analytical method was used to confirm the presence and 
amount of BZP and/or TFMPP in 7 ante- and post- mortem cases from the 
Cuyahoga County Coroner’s Office. These cases presented to the 
Coroner for various reasons: accidental or intentional death, or drug 
testing cases for police investigations. Each sample initially tested 
positive for Amphetamines Enzyme Multiplied Immunoassay Technique 
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(EMIT) using a Viva-Jr® Drug Testing System (Sylva Dade Behring – 
Siemens, Deerfield, IL, USA) and subsequently confirmed negative for 
amphetamines by GC/MS. It is known that BZP and TFMPP have some 
cross-reactivity with the Amphetamine EMIT assay [18], so after the 
negative amphetamine GC/MS test, BZP and TFMPP were suspected. All 
blood samples were extracted from the femoral artery, except case #6, 
which was sampled directly from the heart. 
 
3.3. Results and discussion 
 
3.3.1. Optimization of MS/MS parameters 
 
The mass spectrometer settings were optimized by direct infusion of each 
analyte using the “Compound Optimization” feature of Analyst software at 
a concentration of 10 ng/mL in ACN/water (50/50, v/v) at a rate of 10 
µL/min. 190 µL/min of the mobile phase was joined by T-connection at the 
ESI source to make up the flow rate difference.  The major parent ions of 
177.1, 231.1, and 191.1 m/z representative of [BZP+H]+, [TFMPP+H]+, 
and the [IS+H]+ produced product ions of 91.0, 188.0, and 105.0 m/z 
respectively (figure 3.5 A-F). These mass transitions were used for 
analyte quantification in MRM mode. 
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Figure 3.5, Representative structures, full scan and fragmentation spectra 
of (A,B) BZP, (C,D) TFMPP, and (E,F) the internal standard, 2-MBZP. 
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3.3.2.  Chromatographic separation and carryover 
 
BZP and TFMPP are basic compounds with calculated pKa of 8.79 and 
9.59 and LogP of 1.35 and 2.43 respectively (data from ACD/Labs 
software v8.14).  Even though each analyte contains a phenyl moiety, the 
basic character of BZP especially presents difficulty for the 
chromatographic separation. While a lower pH aids in more efficient 
ionization translating to better sensitivity in the mass spectrometer, the 
charged state significantly reduces the retention of the analytes on 
traditional reversed phase columns such as C4, C8, and C18. To 
overcome this, a Waters XBridge™ C6-Phenyl (3.5 µm, 2.1 x 50 mm) 
column was employed to take advantage of the phenyl moiety of BZP and 
TFMPP and increase retention of the analytes by hydrophobic interaction.  
 
Optimal separation of BZP and TFMPP was achieved using a mobile 
phase consisting of 45% 10 mM ammonium acetate (pH 5.75) 55% 
methanol (v/v) resulting in retention times of 1.7, 2.4, and 2.9 min for BZP, 
the IS, and TFMPP respectively (figure 3.6). The lower limit of quantitation 
(LLOQ) was 0.500 ng/mL, while the upper limit of quantification (ULOQ) 
was 250 ng/mL for BZP and 500 ng/mL for TFMPP. 
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Figure 3.6, Representative MRM chromatograms of BZP (0.500 ng/mL), 2-
MBZP (5 ng/mL), and TFMPP  (0.500 ng/mL) in human hemolyzed blood. 
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During the initial efforts to develop the HPLC separation method, it was 
discovered that there was carryover of the analytes that was associated 
with the autosampler needle. This carryover was unpredictable, occurred 
at concentrations within the calibration range, and was not controlled by 
typical or exotic needle washing solutions (e.g., 50/50 MeOH or 
ACN/water, 50/50/0.1 MeOH or ACN/water/formic acid, 100 mM perchloric 
acid solution with MeOH or ACN [22]). It was determined that 50/50/0.1 
methanol/water/ammonium hydroxide as the needle wash solution was 
sufficient to control the carryover. Mobile phase blank injection after of 10 
µg/mL in 50% acetonitrile shows no carryover for BZP, and an 
insignificant amount for TFMPP (figure 3.7).  
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Figure 3.7, Carryover control: (A) injection of mobile phase blank after 10 
µg/mL in 50% acetonitrile and (B) LLOQ chromatogram of the method. 
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3.3.3. Method validation results 
 
The method has been validated according to the parameters listed in 3.2.6 
in hemolyzed blood and urine. Bile and vitreous humor were diluted 10 
times in hemolyzed and their recovery, matrix factor, and dilution integrity 
established. 
 
3.3.3.1.  Calibration curves 
 
The linearity of the method for BZP was 0.500 – 250 ng/mL where TFMPP 
was 0.500 – 500 ng/mL. The curves were established by three injections 
each of seven non-zero standards (0.500, 1.00, 5.00, 10.0, 50.0, 100, and 
250 ng/mL for BZP and 0.500, 1.00, 5.00, 10.0, 50.0, 100, and 500 ng/mL 
for TFMPP) on three different days and submitted to linear regression with 
1/x weighting. The results of this analysis are represented in table 3.1. 
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Table 3.1, Calibration equations in hemolyzed blood and urine over three 
separate days. 
 
  
  
Matrix  Equation for BZP r
2 
Hemolyzed Blood 
 
y=0.0139(±0.0019)x + -0.0016(±0.0012) 0.9994 
Urine 
 
y=0.0148(±0.0005)x + 0.0006(±0.0005) 0.9998 
    
  
Equation for TFMPP r2 
Hemolyzed Blood 
 
y=0.0045(±0.0022)x + -0.0004(±0.0012) 0.9994 
Urine   y=0.0065(±0.0005)x + 0.0004(±0.0004) 0.9997 
n = 9 
Equation in the form y=mx + b 
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3.3.3.2. Recovery and matrix effects 
 
The sample extraction method used in this work is a variation of the 
“dilute and shoot” technique [23]. Here, 4x ACN was used to deproteinize 
the biomatrix and after centrifugation, the supernatant is diluted with equal 
volume of 10 mM ammonium acetate, pH 5.75 to a final overall dilution of 
10x. This “crash and shoot” technique serves dual purpose: to extend the 
linear range of the method without compromising sensitivity and to 
effectively dilute out any potential ion suppressing or enhancing 
components. 
 
Recovery and matrix factor was determined in hemolyzed blood, urine, 
bile, and vitreous humor at 1.50, 15.0, and 150 ng/mL, representing the 
calibration range. Bile and vitreous humor samples were prepared as 15.0, 
150, and 1.50 x 103 and diluted 10x in hemolyzed blood to facilitate  
matrix matching for the study. As summarized in table 3.2, recovery 
ranged from 87% to 108% for BZP and 94% to 109% for TFMPP over the 
concentration range in all the matrices. Matrix factor, a measure of 
ionization suppression or enhancement, ranged from 0.90 to 1.03 for BZP 
and from 0.91 to 10.8 for TFMPP. These results suggest that the “crash 
and shoot” sample preparation method was successful and sufficient to 
extract the analytes and to minimize excessive matrix effects.  
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Table 3.2, Summary of recovery and matrix factor in the biomatrices. 
 
  
Analyte
Nominal 
Concentration 
(ng/mL) 
Recovery 
± SD (%) MF
a ± SD Analyte
Nominal 
Concentration 
(ng/mL) 
Recovery 
± SD (%) MF
a ± SD 
1.50 100 ± 3 1.0 ± 0.01 1.50 100 ± 3 1.08 ± 0.04
15.0 103 ± 3 0.91 ± 0.02 15.0 100 ± 0.3 1.07 ± 0.01
150. 99 ± 2 0.92 ± 0.02 150. 99 ± 2 1.03 ± 0.01
1.50 98 ± 1 0.96 ± 0.01 1.50 101 ± 1 1.02 ± 0.03
15.0 87 ± 1 1.03 ± 0.01 15.0 100 ± 1 1.04 ± 0.02
150. 87 ± 2 0.97 ± 0.01 150. 94 ± 1 0.98 ± 0.01
1.50 104 ± 2 0.94 ± 0.05 1.50 108 ± 9 0.94 ± 0.04
15.0 104 ± 2 0.97 ± 0.01 15.0 109 ± 1 1.05 ± 0.03
150. 97 ± 4 0.97 ± 0.03 150. 109 ± 2 1.01 ± 0.05
1.50 108 ± 10 0.92 ± 0.06 1.50 106 ± 3 0.94 ± 0.02
15.0 97 ± 1 0.90 ± 0.02 15.0 107 ± 2 0.91 ± 0.02
150. 101 ± 1 0.91 ± 0.02 150. 109 ± 2 0.92 ± 0.01
Each datum point calculated from triplicate measurements.
a Matrix Factor (MF)  = [(mean area ratios in spiked extract) / (mean area ratios in mobile phase)]
BZP
BZP
Vitreous Humor TFMPPBZP
Urine
Hemolyzed Blood
Bile BZP
TFMPP
TFMPP
TFMPP
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3.3.3.3. Accuracy, precision, dilution, and concentration integrity 
 
The accuracy and precision of the method is established to ensure the 
analytical method can be relied on to quantify BZP and TFMPP in 
unknown samples. Here, accuracy and precision were determined on 
three separate days to ensure method robustness. A summary of the 
intra- (within) and inter- (between) day results is presented in tables 3.3 
and 3.4.  As listed, the method had accuracy 90% - 105% and precision 
≤8% over the concentration range for both of the matrices.  
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Table 3.3, Summary of accuracy and precision in hemolyzed human blood. 
  
Intra- Inter-
Hemolyzed 
Blood
Nominal 
Concentration 
(ng/mL)
Mean Analyte 
Concentrationa 
± SD (ng/mL)
Accuracy 
(%)
Precision 
(%CV)
Mean Analyte 
Concentrationb 
± SD (ng/mL)
Accuracy 
(%)
Precision 
(%CV)
BZP 0.500 0.49 ± 0.02 99 3
1.50 1.46 ± 0.03 97 2 1.48 ± 0.03 99 2
15.0 14.2 ± 1 95 7 14.1 ± 0.8 97 5
150. 145 ± 5 97 3 141 ± 7 94 5
TFMPP 0.500 0.45 ± 0.02 90 3
1.50 1.50 ± 0.01 100 7 1.53 ± 0.04 102 2
15.0 14.7 ± 07 98 5 14.5 ± 1 97 8
150. 147 ± 10 98 7 151 ± 9 101 6
Accuracy % = (measured/nominal) × 100%.
a Each datum point calculated by one injection each of five separate samples.
b Each datum point calculated by one injection each of five separate samples on three different days.
%CV = (standard deviation/mean) × 100%
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Table 3.4, Summary of accuracy and precision in human urine. 
 
 
  
Intra- Inter-
Urine
Nominal 
Concentration 
(ng/mL)
Mean Analyte 
Concentrationa 
± SD (ng/mL)
Accuracy 
(%)
Precision 
(%CV)
Mean Analyte 
Concentrationb 
± SD (ng/mL)
Accuracy 
(%)
Precision 
(%CV)
BZP 0.500 0.524 ± 0.039 105 7
1.50 1.45 ± 0.04 99 3 1.50 ± 0.04 100 3
15.0 14.8 ± 0.2 99 1 15.4 ± 0.8 102 4
150. 141 ± 2 94 2 152 ± 10 101 7
TFMPP 0.500 0.492 ± 0.042 98 8
1.50 1.34 ± 0.03 90 2 1.48 ± 0.11 98 8
15.0 13.6 ± 0.1 91 1 14.7 ± 1 99 7
150. 140 ± 1 93 1 152 ± 11 101 7
Accuracy % = (measured/nominal) × 100%.
a Each datum point calculated by one injection each of five separate samples.
b Each datum point calculated by one injection each of five separate samples on three different days.
%CV = (standard deviation/mean) × 100%
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Since drugs of abuse are often taken in large doses, it was important to 
establish the dilution ability of the method. To save sample processing 
time, dilution after extraction was investigated by diluting the QC or 
unknown with a solution of 5 ng/mL 2-MBZP in 50% ACN. Sample 
concentration studies were also investigated, as this procedure might be 
useful for badly decomposed samples. Here, the samples were extracted 
as described in section 3.2.4, but instead of diluting the sample in water, 
the sample is dried under a gentle stream of nitrogen at 25 °C and 
reconstituted in 2 times the volume of 50% ACN for analysis. As 
summarized in table 3.5 dilution after extraction up to 1000 times and 
concentration up to 10 times yielded good results where accuracy ranged 
from 89% to 101% and precision was always ≤5% for both analytes over 
the four matrices.  These results suggest that samples whose 
concentration lies above or below the calibration range may be either re-
extracted and concentrated, or diluted directly from the autosampler with 
confidence.  
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Table 3.5, Summary of dilution and concentration studies in the 
biomatrices. 
 
  
BZP 5000 1000 5 4.90 ± 0.03 98 3
TFMPP 5000 1000 5 4.45 ± 0.04 89 1
BZP 0.5 10 5 4.49 ± 0.03 90 1
5000 1000 5 4.48 ± 0.06 90 1
TFMPP 0.5 10 5 4.43 ± 0.1 89 2
5000 1000 5 4.57 ± 0.2 92 5
BZP 500 100 5 5.07 ± 0.1 101 2
TFMPP 500 100 5 4.93 ± 0.2 99 4
BZP 500 100 5 5.01 ± 0.03 101 1
TFMPP 500 100 5 4.66 ± 0.02 93 1
Hemolyzed Blood 
Urine
Bile
Vitreous Humor  
Each datum point calculated from triplicate measurements.
Initial 
Concentration 
(ng/mL) 
Analyte Dilution Factor
Concentration 
Factor
Nominal 
Concentration 
(ng/mL)
Measured 
Concentration 
(ng/mL)
Accuracy 
(%)
Precision 
(%CV)
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3.3.3.4. Stability 
 
QC samples were analyzed after being subjected to conditions that would 
approximate potential handling conditions. Stability of the analytes up to 
24 hours in the matrix (before extraction) and in the autosampler (after 
extraction) as well as after three consecutive freeze and thaw cycles were 
performed. The results are listed in table 3.6 and demonstrate sufficient 
stability for the analytes under standard working conditions. 
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Table 3.6, Summary of stability in hemolyzed blood and urine. 
 
  
Hemolyzed 
Blood Urine
BZP 1.50 98 ± 3 99 ± 3
15.0 105 ± 6 97 ± 2
150. 94 ± 4 94 ± 1
TFMPP 1.50 93 ± 1 95 ± 4
15.0 93 ± 4 93 ± 1
150. 103 ± 9 90 ± 2
BZP 1.50 103 ± 4 97 ± 3
15.0 102 ± 1 98 ± 1
150. 102 ± 1 98 ± 2
TFMPP 1.50 95 ± 4 97 ± 3
15.0 95 ± 4 104 ± 1
150. 95 ± 2 104 ± 2
BZP 1.50 95 ± 2 97 ± 2
15.0 97 ± 2 102 ± 2
150. 96 ± 1 101 ± 1
TFMPP 1.50 91 ± 2 98 ± 4
15.0 93 ± 1 105 ± 2
150. 95 ± 1 102 ± 4
Recovery ±  SD (%)
Matrix Stability at room 
temperature for 24 hours 
Autosampler Stability at 
4°C  for 24 hours 
3 Freeze-thaw cycles
Each datum point calculated from triplicate measurements.
Nominal 
Concentration 
(ng/mL)
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3.3.4. Application to ante-and post-mortem samples 
 
The method was applied to confirm the presence and amount of BZP and 
TFMPP in 7 cases presented to the Cuyahoga County Coroner’s Office. 
These samples tested positive for Amphetamines by EMIT assay. 
Following GC/MS analysis, it was found that the substance showing 
positive in the immunoassay was not in fact amphetamine. Analysis with 
the developed LC-MS/MS method in this work confirmed that the 
substances were BZP and/or TFMPP. The results of the antemortem 
samples are listed in table 3.7, and postmortem in table 3.8.  
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Table 3.7, Results of analysis in ante-mortem samples. 
 
 
 
 
 
 
 
 
Case Matrix BZP  (ng/mL) 
TFMPP  
 (ng/mL) 
Other Drugs 
Present Circumstance  
2 Blood 47.0 ± 0.4 0.059 ± 0.002 
Drug-Facilitated 
Sexual Assault 
Urine 
 
 
6.27 x104 ± 1.30 x103 
 
 
464 ± 44 
 
 
THC-COOH, 
Oxazepam, 
Temazepam 
3 
 
Urine 
 
3.61 x104 ± 808 
 
1.03 x103 ± 23 
 
Cocaine, THC-
COOH, GHB 
Drug-Facilitated 
Sexual Assault 
7 
 
 
Urine 
 
 
1.23 x104 ± 58 
 
 
1.13 x103 ± 21 
 
 
Ethanol, MDMA, 
MDA, THC-
COOH, 
Methamphetamine  
Drug-Facilitated 
Sexual Assault 
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Table 3.8, Results of analysis in post-mortem samples. 
 
 
  
Case Matrix BZP  (ng/mL) 
TFMPP  
 (ng/mL) 
Other Drugs 
Present Circumstance  
1 Vitreous Humor 113 ± 1  BLOQ Ethanol 
Gunshot 
Wound 
4 Blood 778 ± 38 10.2 ± 0 Gunshot 
Wound Urine 5.51 x10
4 ± 1.41 x103 2.50 x103 ± 57 THC-COOH  
Bile 1.84 x103 ± 17 398 ± 11 
5 Blood 1.07 x103 ± 26 34.7 ± 0.6 Ethanol 
Struck by Car Urine 
 
3.68 x104 ± 1.20 x103 
 
1.77 x103 ± 99 
 
Ethanol, THC-
COOH, 
Dextromethorphan 
6 
 
Blood 
 
 
761 ± 4 
 
 
85.1 ± 1.3 
 
 
Cocaine, Morphine, 
Oxycodone, 
Diazepam, 
Temazepam, MDMA 
Acute 
Intoxication by 
Cocaine 
Urine 
 
 
 
8.02 x103 ± 76 
 
 
 
788 ± 17 
 
 
 
Cocaine, 
Methamphetamine, 
Oxycodone, MDMA, 
MDA 
Bile 1.57 x104 ± 153 5.59 x103 ± 101 
Vitreous 
Humor 599 ± 20 44.7 ± 3.2 
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3.4. Conclusion 
 
This work describes a sensitive and robust LC-MS/MS method for the 
analytical determination of the drugs of abuse BZP and TFMPP in human 
hemolyzed blood, urine, bile, and vitreous humor. The method is linear 
from 0.500 ng/mL to 250 ng/mL for BZP and 500 ng/mL for TFMPP and 
can accommodate concentration to 10 times and dilution to 1000 times. 
The dilution of samples may be performed after extraction for ease and 
speed of analysis. Validation parameters performed include recovery, 
matrix factor, intra- and inter-day accuracy and precision, and stability 
under common analysis conditions. The column used for analysis is a 
Waters XBridge™ C6-Phenyl column and shows enhanced retention for 
the highly polar analytes. This column ensures versatility of the method 
and may be amended to include other piperazine derivatives in the future. 
The sensitive nature of the method lends itself to many applications where 
sensitivity is desired, including fluid spotting on paper and highly 
decomposed samples. 
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CHAPTER IV 
 
INSIGHTS INTO THE INACTIVATION OF 
β-LACTAMASE ENZYMES FOR ANTIBIOTIC RESISTANCE BY MASS 
SPECTROMETRY 
 
4.1   Introduction 
 
Bacterial cell walls are made up of peptidoglycan polymers of N-acetyl-
muramic acid (NAM) and N-acetylglucosamine (NAG) (figure 4.1) assembled 
together by transpeptidases called penicillin binding proteins (PBP) [1]. 
Penicillin-type (β-lactam) antibiotics bind to and are then catalyzed by the 
PBP’s in the crosslinking of NAG-NAM peptidoglycan as they are similar in 
structure to D-alanine-D-alanine in the tetra-peptide side chain [2] (figure 
4.2). The incorporation of penicillin-type antibiotics results in a compromised 
cell wall and eventually death. Bacteria have developed a mechanism to 
circumvent the action of β-lactam antibiotics, such as penicillin, by the 
development of β-lactamase enzymes. β-Lactamase enzymes hydrolyze the 
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lactam ring effectively rendering these compounds useless to inhibit PBP cell 
wall synthesis (see figure). 
 
Over 850 β-lactamase enzymes have been identified to date [3]. Ever-
changing bacteria are quickly outsmarting the current arsenal of antibiotics. 
To help improve the action of antibiotics, β-lactamase inhibitors have been 
developed. This work describes the inactivation of three β-lactamase 
enzymes as studied by the use of mass spectrometry. The works thus far 
described in this thesis have focused on quantitation of small molecules by 
liquid chromatography – tandem  mass spectrometry. This final chapter will 
demonstrate an additional functionality of mass spectrometry, specifically the 
use of quadrupole time-of-flight to measure and characterize β-lactamase 
proteins and their interactions with small molecules. Characterizations of 
these interactions and correlation to available kinetic data will be presented. 
 
4.1.1   Bacterial Resistance 
 
Bacteria reproduce quickly, and this reproduction allows for fast 
incorporation of mutations that could prove to be advantageous to their 
survival. Mutations occur readily in β-lactamase enzymes [4] as well as 
PBPs [5] causing decreased efficacy of lactam antibiotics. Both mechanisms 
are detrimental to lactam antibiotics, but this work will focus on β-lactamase 
enzyme mutations. Tactics to increase the efficacy of lactam antibiotics 
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include the co-administration of β-lactamase inhibitors. The inhibitors bind to 
the active site of the β-lactamase more favorably and tightly than the 
antibiotic (substrate) and therefore allow the antibiotic time to work and 
weaken the cell structure. Commercially, there are four FDA-approved 
inhibitor/antibiotic combinations in the USA, table, 4.1 and figure 4.3 [3]. 
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Figure 4.1, Structures of NAM and NAG as well as a peptidoglycan monomer. 
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Figure 4.2, Penicillin incorporation into the peptidoglycan crosslinker 
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Trade Names of 
antibiotic-
inhibitor 
combinations 
 
β-Lactam 
antibiotic 
 
β-Lactam  
Inhibitor 
Augmentin Amoxicillin Clavulanate 
Timentin® Ticarcillin Clavulanate 
Unasyn® Ampicillin Sulbactam 
Zosyn® Piperacillin Tazobactam 
 
Table 4.1, Commercially available inhibitor/antibiotic combinations  
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Figure 4.3, Structures of commercially available lactam antibiotics and 
inhibitor combinations 
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4.1.2  β-Lactamase Classes  
 
There are four classes of β-lactamase enzymes categorized by sequence 
homology. Each class has differences in substrate activity where structural 
and/or amino acid residue location influence their inactivation. Classes A, C, 
and D β-lactamases have a catalytic serine in their active sites where Class 
B β-lactamases utilize Zn2+ [3]. There are only three inhibitors available for 
clinical administration, but many others in different phases of research. 
Figure 4.4 shows the basic core structure of four different classes of 
inhibitors [6].  
 
Class A β-lactamases are the most common in occurrence and appear in 
both gram-positive and gram-negative bacteria; they include TEM and SHV 
enzymes and are susceptible to clavulanate, tazobactam, and to a lesser 
extent, sulbactam [4]. An additional sub-category, the extended spectrum β-
lactamases, ESBL, includes the methicillin-resistant S. aureas, MRSA [7]. 
Others include the Class A carbapenemase KPC [8], Class C 
cephalosporinase FOX [9], and Class D oxacillinase OXA [10]. An emerging 
threat is the recently discovered Class B metallo-β-lactamase, NDM [11]. 
NDM-1 has proven to have a broad resistance profile and shown the ability 
to apparently move to more than one species of bacteria [11]. This work will 
focus on inactivation of both Class A β-lactamase and carbapenemase 
enzymes.  
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Figure 4.4, Core structures of some inhibitor types  
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4.1.3  β-Lactam Hydrolysis 
 
The Class A β-lactamase enzymes first acylate and then hydrolyze 
antibiotics and to a slower extent, the inhibitors. The reaction can be 
represented by the simplified scheme S1.   
 
    (S1) 
 
The enzyme, E, transiently binds to the substrate, S, and forms a complex. 
The enzyme then acylates the substrate in the active site, and on 
deacylation, the substrate is released as a product. The rates of each step 
can be calculated by kon, koff, k2, and k3. kon is the association constant, and 
koff is the dissociation constant. k2 is the rate of acylation where k3 is the rate 
of deacylation. We can calculate the kinetics by the utilization of the work of 
Michaelis and Menten [12].  
 
The above scheme is a very simplified example of acylation and deacylation. 
In reality, the enzyme goes through a number of intermediate steps before 
deacylation and releasing the product and is represented in scheme S2 [3, 
13].  
E + I E : I E - Ik on
k off
k2 (acylation) E + P1
k3 (deacylation)
k7
E - I  (imine)
E - I   (inactivation products)
H2O
H2O
E + P2
k4H+
k6
k5k-5
E -T (cis- and trans-enamine
  S :S -S 
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 (S2) 
 
This updated scheme reveals transient E-S* imine, E-S** with additional 
reaction products, E-T enamine tautomer, as well as regenerated enzyme 
and product, E+P1 and E+P2 [3]. Portions of the reaction scheme can be 
measured by such techniques as UV spectroscopy and mass spectrometry 
(figure 4.5). Figure 4.6 depicts an accepted inactivation scheme for Class A 
β-lactamase enzymes where two serines at positions 70 and 130 work with 
H2O to acylate and hydrolyze the substrate [14]. 
 
The Michaelis constant, Km, a measure of enzyme:substrate affinity where a 
smaller number corresponds to high affinity, can be calculated as: 
 
       1 
 
E + I E : I E - Ik on
k off
k2 (acylation) E + P1
k3 (deacylation)
k7
E - I  (imine)
E - I   (inactivation products)
H2O
H2O
E + P2
k4H+
k6
k5k-5
E -T (cis- and trans-enamine)
E + S :S -S 
E-S! 
E-S!! 
Km =
k3 (koff + k2 ) / kon( )
k2 + k3( )
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The turnover number, kcat/kinact, a measure of the number of molecules of 
inhibitor hydrolyzed by the enzyme before irreversible inactivation, can be 
calculated as: 
 
     2 
 
Calculating kinetics is done by measuring the residual activity or competitive 
binding of the β-lactamase enzyme by the chromogenic substrate, nitrocefin 
[15]. Active enzyme will hydrolyze nitrocefin and the absorbance at 482 nm 
is measured.  
Turnover number = kcat / kinact = k3 / k4
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Figure 4.5, Measurement of β-lactamase enzyme inactivation  
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Figure 4.6, Class A β-lactamase enzyme inactivation scheme  
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4.2   Materials and Methods 
 
4.2.1  Preparation of enzymes for analysis 
 
The β-lactamase enzymes used in this study are the Class A serine β-
lactamase SHV-1 and the Class A carbapenemase KPC-2. Mutagenesis of 
KPC-2 was performed by site-directed mutagenesis. The β-lactamase were 
expressed in Escherichia coli strain DH108 or similar and described 
previously, [13, 14, 16]. All lysed and fractionated supernatants were 
subjected to preparative isoelectric focusing followed by ion exchange liquid 
chromatography according to the previously published methods [13, 17, 18]. 
 
4.2.2  Antibiotic Susceptibility and Kinetics 
 
Minimum Inhibitory Concentrations (MIC) to resolve antibiotic susceptibility 
on E. coli DHB10B expressing blaKPC-2 was determined by agar broth dilution 
method described previously [18, 19]. Residual activity was determined at 22 
°C in an Agilent 8453 Diode Array Spectrophotometer (Santa Clara, CA) 
using nitrocefin (BD Biosciences) and the extinction coefficient, ε = 17,400 M-
1cm-1 at 482 nm. KM and turnover number were calculated using modified 
versions of equations 1 and 2 in section 4.1.3. For complete details of the 
concentrations and parameters used, refer to references [17] and [19] for 
SHV-1, and references [13] and [18] for KPC-2 and KPC-2 R220K. 
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4.2.3  Inactivation of β-lactamase enzymes 
 
Purified β-lactamase enzymes at concentrations of 10 µM in PBS for KPC-2 
or 0.45 µM in 10 mM diethanolamine for SHV-1 were incubated with either 
sulbactam or clavulanate at 22 °C then the reaction stopped at specific 
timepoints by the addition of 0.1% trifluoroacetic acid. The proteins were 
then desalted using C18 ZipTips (Millipore, Bedford MA, USA) according to 
the protocol recommended by the manufacturer. The protein was eluted from 
the ZipTips by 50 µL of acetonitrile/H2O/formic acid (50:49:1) for analysis.   
 
4.2.4  Electrospray Ionization Mass Spectrometry (ESI-MS) 
 
The infusion analysis was carried out on an AB Sciex (Foster City, CA, USA) 
QSTAR®-Elite quadrupole-orthogonal acceleration time-of-flight (Q-TOF) 
mass spectrometer equipped with a TurboIonSpray™ Source and an 
integrated syringe pump.  Mass calibration was performed in the positive 
mode with Renin solution using the recommended instrument protocol. The 
protein eluate was then infused into the mass spectrometer at a flow rate of 
5 µL/min.   Mass spectra were acquired using Analyst QS v2.0 software with 
80-150 MCA cycles and an accumulation time of 1.5 s from 600 – 2800 amu. 
Temperatures and gases were as follows: GS1 = 20, GS2 = 5, CUR = 15, IS 
= 5500, and TEM = 300.  The mass spectra were deconvoluted by 
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BioAnalyst™2.0 software using the Bayesian protein reconstruction 
algorithm. 
 
4.3  Results and Discussion 
 
4.3.1  Antibiotic susceptibility and kinetic analysis of sulbactam and 
clavulanate on SHV-2, KPC-2 and mutants 
 
Previously, our lab investigated the MICs of bacteria expressing blaSHV-1 to 
ampicillin and piperacillin as well as the kinetics with clavulanate [19]. The 
mutation at this position was shown to make the most difference with 
inhibitor susceptibility [17]. Bacterial cells expressing blaKPC-2 and mutation 
arginine to lysine at ambler position 220 were tested against ampicillin, 
piperacillin, as well as ampicillin and clavulanate or sulbactam combinations. 
As shown in table 4.2, SHV-1 is resistant to antibiotics with 16000 mg/L of 
ampicillin required for growth inhibition. On incubation with the inhibitor 
clavulanate, the susceptibility maintained indicating resistance (4 mg/L). 
Conversely, KPC-2 and mutation R220K were each susceptible to ampicillin 
at 256 mg/L and on the addition of clavulanate, showing decreased 
resistance (from 32 mg/L for WT to ≤1 for R220K). These results suggest 
that the mutation investigated has a direct impact on the susceptibility of the 
enzyme to antibiotics and inhibitors.  
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To further understand the impact of the mutation, the kinetics of inactivation 
were calculated. With wild type (WT) SHV-1, we see low-to-sub micromolar 
values for the dissociation (KI) of the enzyme-inhibitor complex 
demonstrating that SHV-1 is less resistant to sulbactam inhibition (a higher 
concentration of sulbactam was needed to inhibit the enzyme) (table 4.3). A 
similar situation is seen in KPC-2 with respect to the R220K mutation. 
Although WT KPC-2 is somewhat resistant to sulbactam, the R220K 
mutation makes the enzyme more susceptible to inhibition. The binding (Km) 
of clavulanate to KPC-2 is 25 µM, where the R220K mutation is 14 µM. 
Additionally, the R220K mutant loses the ability to hydrolyze clavulanate; the 
kcat of WT KPC-2 is 18 s-1 and was undetectable for the R220K mutant.  
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MIC (mg/L) 
 
 Ampicillin  Piperacillin Ampicillin/ clavulanateb 
Ampicillin/ 
sulbactamc 
SHV-1a 16000 2000 4  
    
KPC-2 256 128 32b 512b 
    
KPC-2 R220K 256 16 ≤1 8 
a From reference 17 
b Inhibitor evaluated in the presence of 50 µg/mL of ampicillin 
c Determined using the K. pneumoniae strain from which blaKPC-2 was 
cloned 
 
 
 
Table 4.2. MICs of SHV-1 and KPC-2 and mutants  
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Table 4.3. Inhibitor kinetics of SHV-1 and KPC-2 and mutants  
 
Inhibitor Kinetics 
 
Sulbactam 
 
Clavulanate 
 
Km(µM) kcat (s
-1) kcat/kiinact  Km(µM) kcat (s
-1) kcat/kiinact 
KPC-2 184 ± 18 n/a 3000  25 ± 3 18 ± 2 9000 
      
KPC-2 R220K 146 ± 15 n/a 250   14 ± 1 n/d 250 
 
KI(µM)
a kcat (s
-1) kcat/kiinact  KI(µM)
b kcat (s
-1) kcat/kiinact 
SHV-1 8.6 ± 0.7 730 ± 40 13000 ± 100 0.14 1.2 40 
a For details of KI calculation, see reference 19 
b For details of KI calculation, see reference 17 
n/a = not performed 
      n/d = not detectable 
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4.3.2  Mass Spectrometric studies of the inhibition of SHV-1 
 
To understand the nature of the binding and intermediate formation involved 
in SHV-1 and KPC-2 inactivation, positive electrospray mass spectrometry 
was employed. Increasing inhibitor:enzyme ratios were investigated and the 
reactions stopped at specific timepoints for mass spectrometric analysis. 
Figures 4.7 and 4.8 show the reaction of 0.45 µM SHV-1 with 500x and 
5000x (mol/mol) sulbactam (225 and 2250 µM) respectively. With the 
sulbactam concentration 500 times that of SHV-1, we see negligible adduct 
formation at room temperature over a 24 hour period. When the 
concentration of sulbactam is increased to 5000 times (2250 µM), multiple 
adducts are formed, +54, +72, +90, +106, +153 and +171 m/z (table 4.4). 
The adducts at +18 and +36 m/z likely correspond to [M + H + H2O] and [M 
+ H + 2H2O] respectively. These results correspond to the MIC and kinetic 
analysis showing that SHV-1 β-lactamase does indeed bind with the inhibitor 
and allows the bacteria to become more susceptible to antibiotics. 
Sulbactam is a substrate that binds to the active site and turns over at a 
much slower rate, thus occupying the active site and allowing for a longer 
half-life of antibiotic in the bacterial system.  
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Figure 4.7. Timed mass spectrometric analysis of 500:1 sulbactam/SHV-1 
incubation  
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Figure 4.8. Timed mass spectrometric analysis of 5000:1 sulbactam/SHV-1 
incubation   
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Table 4.4. Adduct formation in 5000:1 (mol/mol) sulbactam/SHV-1 
  
(A) 5000:1 (mol/mol) sulbactam/SHV-1
WT (amu)
Deconvoluted 
Mass  (amu)
Δ mass   
(±3 amu)
28872
28926 54
28944 72
28962 90
28978 106
29025 153
29043 171
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4.3.3  Mass Spectrometric studies of the inhibition of KPC-2 and KPC-
2 R220K 
 
Similar experiments were performed to elucidate binding information for 
KPC-2. Clavulanate at a ratio of 10,000 mM was incubated with 10 mM KPC-
2 with the reaction stopped at specific timepoints for analysis by mass 
spectrometry. As shown in figure 4.9, WT KPC-2 formed negligible adducts 
with clavulanate, corresponding with the kinetic findings. The specificity, or 
tightness of binding, of KPC-2 was determined to be 25 µm but the turnover 
number (kcat/kinact) is large at 3000 (table 4.3). Comparing these data to the 
R220K mutation, the Km is only slightly smaller at 14 µm, but the turnover 
number is 12 times lower at 250 indicating the inhibitor potentially spends 
more time occupied inside the active site. Listed in table 4.3, the kcat , 
measure of hydrolysis, of KPC-2 is calculated as 18 molecules per second, 
where R220K could not be determined. As illustrated by figure 4.10, 
incubating 100x (mol/mol) clavulanate with the mutation, R220K, adducts are 
visible through mass spectrometry. The inhibitor adducts at +51, +69, and 
+88 (table 4.5) appear at 1 minute, reach a maximum amount at 2.5 – 5 
minutes, and decline thereafter. Figure 4.11 is a graph of the area of the 
deconvoluted mass found by mass spectrometry over time, showing the rise 
and fall of the occurrence of the various adducts. These results, together 
with the kinetic findings, including the loss of hydrolysis on mutation, suggest 
that the mechanism of inactivation of KPC-2 could indeed lie in the binding 
efficiency of the enzyme with clavulanate. 
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Figure 4.9. Timed mass spectrometric analysis of 100:1 clavulanate/KPC-2 
incubation   
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Figure 4.10. Timed mass spectrometric analysis of 100:1 clavulanate/KPC-2 
R220K incubation  
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Table 4.5. Adduct formation in 100:1 (mol/mol) clavulanate/KPC R220K 
 
 
 
 
 
 
 
  
100:1 (mol/mol) clavulanate/KPC R220K
WT (amu)
Deconvoluted 
Mass  (amu)
Δ mass   
(±3 amu)
28147
28198 51
28216 69
28235 88
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Figure 4.11. Timed mass spectrometric analysis of 100:1 clavulanate/KPC-2 
R220K incubation; graph of the adduct mass areas 
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4.3.4  Proposed inactivation  
 
Timed mass spectrometric analysis of the incubation of β-lactamase 
enzymes with inhibitors gives visual mass-adduct snapshots of the 
progression of inactivation. The analysis of the measured masses 
combined with UV as well as X-ray crystallographic and RAMAN 
spectroscopic techniques helps to build an understanding of the steps to 
inactivation.. Measurement of the enzyme adducts by mass spectrometry 
revealed three common predominant adducts in both SHV-1 and KPC-2: 
+Δ51 (±3), +Δ69 (±3),  +Δ88 (±3), as well as +Δ106 (±3),  +Δ153 (±3), and 
+Δ171 (±3)  in SHV-1.  Figure 4.12 depicts the proposed inactivation scheme for 
SHV-1 by sulbactam [20]. The serine at position 70 in the binding site attacks the 
β-lactam ring, opens, and finally forms the acyl-enzyme complex. The 
secondary ring opens and the reaction continues to an imine, cis- and/or 
trans-enamine, then finally to the inactivation products we visualize by mass 
spectrometry. The imine is converted to an aldehyde (+Δ70) and further to a 
hydrated aldehyde (+Δ88). Serine at position 130 helps to form a bridge and 
make an enol ether (+Δ52) that decomposes to a propynyl enzyme (+Δ52). 
Finally, the products are released and the enzyme regains activity.  A very 
similar reaction scheme applies to the inactivation of KPC-2 by clavulanate 
and is depicted in figure 4.13.  
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Figure 4.12. Proposed inactivation scheme for SHV-1 by sulbactam 
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Figure 4.13. Proposed inactivation scheme for KPC-2 and KPC-2 R220K by 
clavulanate 
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4.4  Conclusion 
 
SHV-1 has the preferred substrates of penicillins and some cephalosporins, 
where KPC-2 has a broad substrate profile that includes the penicillins, 
cephalosporins, and carbapenems [3]. In addition to the ability to hydrolyze a 
variety of antibiotics, these β-lactamases are (semi) resistant to 
commercially available inhibitors. Each β-lactamase can be found primarily 
in Klebsiella pneumoniae and represents a treatment threat to those infected. 
The work to understand how these enzymes can be inhibited will lead to the 
intelligent creation of new inhibitors. The use of mass spectrometry is a 
compliment to the enzyme kinetic work as it can give exact mass to the 
proposed enzyme-inhibitor complexes. 
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